学术周报 · IF≥10
神经内科领域文献阅读汇编
2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Stroke | 4 | IF 11.1 |
| Neuron | 4 | IF 16.9 |
| European journal of preventive cardiology | 4 | IF 10.0 |
| Nature neuroscience | 3 | IF 20.3 |
| Molecular biomedicine | 3 | IF 13.0 |
| Acta neuropathologica | 3 | IF 10.3 |
| Circulation | 3 | IF 41.3 |
| Progress in cardiovascular diseases | 3 | IF 10.6 |
| JAMA neurology | 3 | IF 23.6 |
| Science advances | 2 | IF 13.9 |
1脑血管病与卒中 (30篇)
临床研究 (17篇)
Patients from more deprived backgrounds experience poorer postoperative outcomes. We analysed preoperative characteristics in UK Perioperative Quality Improvement Programme participants according to socioeconomic position to explore opportunities for targeted interventions. Participants were adults aged ≥18 yr undergoing major elective surgery at UK Perioperative Quality Improvement Programme sites. Socioeconomic position was determined using postcode data and the Index of Multiple Deprivation (IMD) standardised aggregate scale of area-level deprivation. Associations between IMD position and patient characteristics, health behaviours, and comorbidities were analysed using descriptive statistics with appropriate parametric and nonparametric testing. Of 55 938 participants included, quintile 1 (most deprived) represented the smallest subgroup (14.2%), with recruitment varying by region and site. Median age was 66 yr with IMD 1 participants 5 yr younger (62 yr) than IMD 5 (67 yr). Deprivation gradients (IMD 5 to 1) were seen for home ownership, occupation, and educational attainment. Prevalences of smoking, inactivity, and obesity increased from IMD 5 to 1. Higher prevalences of major long-term conditions including diabetes mellitus, heart failure, stroke, and ASA physical status 3-4 were observed in more deprived quintiles. Prevalence rates of dementia and renal impairment were similar across quintiles despite the age gradient. Notably, the proportions of patients living with frailty and disability increased with deprivation. Patients presenting for major surgery from more deprived backgrounds do so in poorer overall health. They can encounter barriers to both research participation and available preoperative support. Addressing this unmet need to prevent widening perioperative health inequalities requires interventions tailored to the patient's socioeconomic context.
中文摘要:来自更贫困背景的患者术后结局更差。我们根据社会经济地位分析了英国围手术期质量改进计划参与者的术前特征,以探索针对性干预的机会。参与者为在英国围手术期质量改进计划站点接受大型择期手术的18岁及以上成人。社会经济地位使用邮编数据和多重剥夺指数(IMD)这一地区层面剥夺的标准化汇总量表确定。采用描述性统计及适当的参数和非参数检验分析IMD位置与患者特征、健康行为和合并症之间的关联。共纳入55 938名参与者,第一五分位(最贫困)是最小的亚组(14.2%),招募情况随地区和站点而异。中位年龄为66岁,IMD 1参与者比IMD 5参与者年轻5岁(62岁 vs 67岁)。在住房拥有、职业和教育程度方面可见剥夺梯度(IMD 5至1)。吸烟、缺乏活动和肥胖的患病率从IMD 5至1升高。在更贫困的五分位中观察到糖尿病、心力衰竭、卒中和ASA身体状况分级3~4级等主要长期疾病患病率更高。尽管存在年龄梯度,痴呆和肾功能损害的患病率在各五分位间相似。衰弱和残疾患者比例随剥夺程度增加而上升。来自更贫困背景接受大型手术的患者整体健康状况更差。他们可能在研究参与和可获得的术前支持两方面遇到障碍。解决这一未满足需求以防止围手术期健康不平等扩大,需要针对患者社会经济背景量身定制的干预。
White matter hyperintensities (WMH) are a common brain magnetic resonance imaging marker of cerebral small vessel disease and a major risk factor for stroke and dementia, yet the molecular mechanisms governing lesion formation remain incompletely understood. We sought to identify circulating proteins that lie upstream of WMH and influence related clinical manifestations. We conducted a 4-stage proteogenomic study. Stage 1 tested a WMH polygenic risk score against 2923 plasma proteins in 52 560 UK Biobank participants (mean age, 56.8 years, 53.9% female, 94.0% White), and candidate proteins against WMH volume in the neuroimaging subset (n=5443; mean age 54.2 years, 53.5% female). Stage 2 applied bidirectional Mendelian randomization, colocalization, and local genetic correlation using cis protein quantitative trait locus and cis expression quantitative trait locus instruments from plasma, vascular, and brain tissue. Stage 3 analyzed single-nucleus RNA sequencing of 8 postmortem periventricular white matter samples (4 WMH lesions, 4 controls; mean age, 81 years; 50% female). Stage 4 tested circulating and genetically predicted protein levels against general cognitive ability. Stages 1 and 2 converged on CTSB (cathepsin B) and ECHDC3 (enoyl-coenzyme A hydratase domain-containing 3). Higher plasma CTSB was associated with lower WMH volume (β=-0.09 [95% CI, -0.13 to -0.05]; n=5260), and Mendelian randomization estimates were directionally consistent across all 5 instrument sets (plasma protein quantitative trait locus β=-0.052 [95% CI, -0.064 to -0.040]), with concordant effects on white matter microstructure, perivascular spaces, and lacunar stroke. Single-nucleus RNA sequencing showed CTSB downregulation within lesions, predominantly in astrocytes (log2 fold change=-1.70) and oligodendrocytes (log2 fold change=-0.48; both false discovery rate P<1×10-20). Higher plasma CTSB (β=0.061 [95% CI, 0.010-0.112]; n=5193) and a cis protein quantitative trait locus polygenic score (β=0.031 [95% CI, 0.009-0.054]; n=8884) predicted better cognitive performance. ECHDC3 showed no consistent association beyond stage 1. Multimodal proteogenomic evidence nominates CTSB as a lesion-suppressed protein associated with lower WMH burden and better cognition, and a candidate therapeutic target for cerebral small vessel disease.
中文摘要:白质高信号(WMH)是脑小血管病常见的脑磁共振成像标志,也是卒中和痴呆的重要危险因素,但控制病灶形成的分子机制仍未完全阐明。研究旨在识别位于WMH上游并影响相关临床表现的循环蛋白。我们开展了四阶段蛋白质基因组学研究。第一阶段在英国生物银行52560名参与者(平均年龄56.8岁,女性占53.9%,白人占94.0%)中检验WMH多基因风险评分与2923种血浆蛋白的关联,并在神经影像亚组(n=5443;平均年龄54.2岁,女性占53.5%)中检验候选蛋白与WMH体积的关联。第二阶段采用来自血浆、血管和脑组织的顺式蛋白数量性状位点与顺式表达数量性状位点工具,进行双向孟德尔随机化、共定位和局部遗传相关性分析。第三阶段对8份死后脑室周围白质样本(4份WMH病灶、4份对照;平均年龄81岁;女性占50%)进行单核RNA测序。第四阶段检验循环蛋白和遗传预测蛋白水平与一般认知能力的关联。第一和第二阶段共同指向CTSB(组织蛋白酶B)和ECHDC3(烯酰辅酶A水合酶结构域包含蛋白3)。血浆CTSB较高与WMH体积较低相关(β=-0.09(95% CI:-0.13至-0.05);n=5260),孟德尔随机化估计在所有5组工具中方向一致(血浆蛋白数量性状位点β=-0.052(95% CI:-0.064至-0.040)),并对白质微结构、血管周围间隙和腔隙性卒中显示一致效应。单核RNA测序显示病灶内CTSB下调,主要见于星形胶质细胞(log2倍数变化=-1.70)和少突胶质细胞(log2倍数变化=-0.48;两者错误发现率P<1×10-20)。血浆CTSB较高(β=0.061(95% CI:0.010至0.112);n=5193)和顺式蛋白数量性状位点多基因评分(β=0.031(95% CI:0.009至0.054);n=8884)预测更好的认知表现。ECHDC3在第一阶段之后未显示一致关联。多模态蛋白质基因组学证据提示,CTSB是一种在病灶中受抑制的蛋白,与较低WMH负荷和更好认知相关,并是脑小血管病的候选治疗靶点。
Health literacy is a critical component of high-quality stroke care. Across the continuum from prevention through recovery, health literacy is strongly associated with functional outcomes and stroke-related morbidity. Despite its importance, it is often overlooked, leaving patients and caregivers overwhelmed by communication demands that exceed their capacity. These mismatches are especially pronounced among individuals with stroke-related cognitive or language impairments, limited English proficiency, socioeconomic disadvantage, or limited digital literacy. This scientific statement synthesizes current evidence on the role of health literacy and communication within stroke systems of care and identifies nurse-led opportunities to advance equity and patient-centered outcomes while recognizing this as a shared interprofessional responsibility. Nurse-led interventions, including teach-back-based education, dyadic psychoeducational programs, and tailored digital support, have demonstrated improvements in stroke knowledge, self-efficacy, quality of life, and caregiver preparedness. However, the literature is marked by methodological heterogeneity. Many studies are underpowered and infrequently use validated health literacy or communication measures. Future directions include standardized assessment of health literacy; literacy-sensitive, nurse-led, and interprofessional care models; workforce training in plain-language and culturally responsive communication; and organizational health literacy principles. Emerging technologies, including telehealth and artificial intelligence, offer promise for improving communication and personalization but require rigorous evaluation to minimize bias and ensure equity and usability.
中文摘要:健康素养是高质量卒中照护的关键组成部分。从预防到康复的连续过程中,健康素养与功能结局和卒中相关疾病负担密切关联。尽管其重要性明确,健康素养仍常被忽视,使患者和照护者被超出其能力的沟通要求所困扰。这种不匹配在伴有卒中相关认知或语言障碍、英语水平有限、社会经济处境不利或数字素养有限的人群中尤为突出。该科学声明综合了健康素养与沟通在卒中照护系统内作用的现有证据,并识别由护士主导、促进公平和以患者为中心结局的机会,同时将其视为跨专业共同责任。护士主导的干预,包括基于教-回法的教育、二元心理教育项目和量身定制的数字支持,已显示可改善卒中知识、自我效能、生活质量和照护者准备度。现有文献存在方法学异质性。许多研究样本量不足,且较少使用经过验证的健康素养或沟通测量工具。未来方向包括健康素养的标准化评估;具有素养敏感性、由护士主导并体现跨专业协作的照护模式;面向工作人员开展简明语言和文化响应性沟通培训;以及组织层面的健康素养原则。远程医疗和人工智能等新兴技术为改善沟通和个性化提供了前景,但需要严格评估以减少偏倚并确保公平性和可用性。
The impact of tirzepatide and dulaglutide on major adverse cardiovascular events (MACE) and heart failure (HF) outcomes according to HF status is unknown. Patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease were treated with tirzepatide up to 15 mg or dulaglutide 1.5 mg weekly (average 4 years). The incidence of MACE-3 [cardiovascular (CV) death, myocardial infarction (MI), stroke], MACE-4 (CV death, MI, stroke, coronary revascularization) and composite of all-cause or CV death and hospitalization or urgent visits for HF were analysed in patients with and without a history of HF. A history of HF (20.3%) was associated with more coronary artery disease and prior MI. Incidences of event categories were higher in the HF group. The hazard ratio (HR) for all-cause death or hospitalization or urgent visits for HF on tirzepatide vs. dulaglutide was 0.83 [95% confidence interval (CI) 0.70-0.99] in patients with HF and 0.88 (95%CI 0.78-1.00) without HF. The HR for CV death or hospitalization or urgent visits for HF was 0.85 (95%CI 0.70-1.03) and 0.96 (95%CI 0.83-1.12), for MACE-3 0.90 (95%CI 0.76-1.08) and 0.93 (95%CI 0.83-1.04), and for MACE-4 0.81 (95%CI 0.69-0.95) and 0.91 (95%CI 0.83-1.00) in patients with and without HF, respectively. The patient-reported outcomes of APPADL and EQ-5D-5L visual analogue scores improved and were higher on tirzepatide in both groups. With overall non-inferiority established, this exploratory analysis revealed lower rates of the composite of all-cause death or HF events, or MACE-4 among patients with T2D and HF treated with tirzepatide compared with dulaglutide.
中文摘要:替尔泊肽和度拉糖肽对主要不良心血管事件(MACE)及心衰结局的影响是否因心衰状态而异尚不清楚。2型糖尿病合并动脉粥样硬化性心血管疾病患者接受替尔泊肽最高15 mg或度拉糖肽1.5 mg每周一次治疗,平均4年。在有和无心衰史患者中分析MACE-3(心血管死亡、心肌梗死、卒中)、MACE-4(心血管死亡、心肌梗死、卒中、冠状动脉血运重建)以及全因死亡或心血管死亡与心衰住院或紧急就诊复合终点的发生率。有心衰史者占20.3%,其冠状动脉疾病和既往心肌梗死更多。心衰组各类事件发生率更高。替尔泊肽对比度拉糖肽的全因死亡或心衰住院或紧急就诊风险比在有心衰史者为0.83(95%CI 0.70-0.99),在无心衰史者为0.88(95%CI 0.78-1.00)。心血管死亡或心衰住院或紧急就诊的风险比分别为0.85(95%CI 0.70-1.03)和0.96(95%CI 0.83-1.12),MACE-3分别为0.90(95%CI 0.76-1.08)和0.93(95%CI 0.83-1.04),MACE-4分别为0.81(95%CI 0.69-0.95)和0.91(95%CI 0.83-1.00)。患者报告的APPADL和EQ-5D-5L视觉模拟评分改善,替尔泊肽组在有和无心衰史患者中均更高。在总体非劣效性成立的基础上,这项探索性分析显示,2型糖尿病合并心衰患者接受替尔泊肽治疗后,全因死亡或心衰事件复合终点以及MACE-4的发生率低于度拉糖肽组。
Glucagon-like peptide-1 (GLP-1) was discovered as an insulinotropic peptide from the gut during a search for candidates for the incretin effect. It was found to also inhibit glucagon secretion and is now considered an important regulator of glucose metabolism. In further investigations of its physiological effects, GLP-1 also inhibited gastrointestinal secretion and motility and inhibited appetite and food intake. Because of these effects, GLP-1 was eventually shown to be able to improve glucose control and beta cell function in patients with type 2 diabetes mellitus (T2DM) and was even associated with weight loss. Because of a very short half-life in the circulation due to renal clearance and enzymatic degradation, stable analogs were developed allowing long-term treatment. Analogs suitable for weekly administration proved highly effective in improving glycemic control in patients with T2DM, and the analogs showed efficacy with respect to weight loss. Moreover, in cardiovascular outcome trials, the agonists were protective against major cardiovascular events and showed renoprotection and neuroprotection. Several observational studies also indicated protection against psychiatric illnesses and dementia. Thus, GLP-1 receptor agonists seem to be an effective weapon against the obesity-associated cardiovascular-kidney-metabolic syndrome affecting millions of patients.
中文摘要:胰高血糖素样肽-1(GLP-1)是在寻找肠促胰岛素效应候选分子时从肠道发现的促胰岛素分泌肽。研究发现它还能抑制胰高血糖素分泌,目前被视为葡萄糖代谢的重要调节因子。对其生理作用的进一步研究显示,GLP-1可抑制胃肠分泌和运动,并抑制食欲和食物摄入。基于这些作用,GLP-1最终被证明能改善2型糖尿病患者的血糖控制和β细胞功能,甚至与体重下降相关。由于经肾脏清除和酶降解导致循环半衰期很短,研究者开发了可长期治疗的稳定类似物。适合每周给药的类似物在改善2型糖尿病患者血糖控制方面高度有效,并在体重下降方面显示疗效。在心血管结局试验中,这些激动剂对主要心血管事件具有保护作用,并显示肾脏保护和神经保护。多项观察性研究还提示其对精神疾病和痴呆具有保护作用。因此,GLP-1受体激动剂似乎是应对影响数百万患者的肥胖相关心血管-肾脏-代谢综合征的有效手段。
Evidence of regional differences in clinical outcomes after intracerebral hemorrhage (ICH) is still scarce. We quantified differential outcomes and response to early intensive blood pressure lowering treatment by region in the Blood pressure in Acute Stroke Collaboration ICH data set. This was an observational analysis of pooled individual participant data from 16 completed randomized controlled trials of blood pressure-lowering treatment in acute ICH, based on the Blood pressure in Acute Stroke Collaboration data set. Generalized linear mixed models with inverse probability of treatment weighting (IPTW) were used to determine the association between regions (Asia [primarily East and South Asia] versus non-Asia) and clinical outcomes including neurological deterioration within 7 days, hematoma expansion at 24 hours (absolute ≥6 mL or relative ≥33%), and death or dependency (modified Rankin Scale scores, 3-6), major disability(modified Rankin Scale score, 3-5), death alone at 90 days. Among 6221 patients (age, 63.3±13.0 years; female 36.4%), 3494 (56.2%) were from Asia. ICH participants from Asia had a significantly reduced risk of death or dependency (unadjusted odds ratio [OR], 0.44 [95% CI, 0.39-0.51]; IPTW-weighted OR, 0.67 [95% CI, 0.58-0.77]); and major disability (unadjusted OR, 0.49 [95% CI, 0.42-0.56]; IPTW-weighted OR, 0.67 [95% CI, 0.57-0.78]) at 90 days, neurological deterioration (unadjusted OR, 0.63 [95% CI, 0.52-0.77]; IPTW-weighted OR, 0.70 [95% CI, 0.56-0.89]) within 7 days, in comparison to those from non-Asia regions. However, there were no differences for hematoma expansion (P=0.97) at 24 hours or death (P=0.23) at 90 days using IPTW. Additionally, there were no significant interactions between blood pressure-lowering treatment and region (Asia versus non-Asia) for either outcome using IPTW. Participants from East and South Asia had a favorable functional recovery and a lower risk of neurological deterioration compared with those from non-Asian regions after adjustment for confounders, with no differences in hematoma expansion at 24 hours after ICH. These findings suggest that future ICH studies on clinical outcomes should consider regional differences.
中文摘要:脑出血后临床结局的区域差异证据仍少。我们在急性卒中血压协作组脑出血数据集中量化了不同区域结局差异及对早期强化降压治疗反应。该研究为观察性分析,汇总16项已完成的急性脑出血降压治疗随机对照试验的个体参与者数据,基于急性卒中血压协作组数据集。采用广义线性混合模型并结合逆概率治疗加权(IPTW),评估区域(亚洲,主要为东亚和南亚,与非亚洲)与临床结局的关联,结局包括7天内神经功能恶化、24小时血肿扩大(绝对≥6 mL或相对≥33%)、90天死亡或依赖(改良Rankin量表评分3-6)、主要残疾(改良Rankin量表评分3-5)及单独死亡。共6221例患者(年龄63.3±13.0岁;女性36.4%),其中3494例(56.2%)来自亚洲。与非亚洲区域相比,亚洲脑出血参与者90天死亡或依赖风险显著降低(未校正比值比[OR] 0.44[95% CI 0.39-0.51];IPTW加权OR 0.67[95% CI 0.58-0.77]),主要残疾风险降低(未校正OR 0.49[95% CI 0.42-0.56];IPTW加权OR 0.67[95% CI 0.57-0.78]),7天内神经功能恶化风险降低(未校正OR 0.63[95% CI 0.52-0.77];IPTW加权OR 0.70[95% CI 0.56-0.89])。采用IPTW时,24小时血肿扩大(P=0.97)或90天死亡(P=0.23)无差异。此外,采用IPTW时,降压治疗与区域(亚洲与非亚洲)对各结局均无显著交互作用。校正混杂因素后,东亚和南亚参与者功能恢复较好,神经功能恶化风险较低,脑出血后24小时血肿扩大无差异。这些发现提示未来脑出血临床结局研究应考虑区域差异。
There is limited information on the heart failure (HF) epidemic and its temporal changes. Current research aimed to report the HF epidemic over the past three decades in the Rotterdam Study, covering the prevalence and incidence of HF, comorbidities and risk determinants. Using data from the population-based Rotterdam cohort, three Epoch groups [Epoch 1990s (1989-1993, N=7,983), Epoch 2000s (1997-2001, N=7,738), and Epoch 2010s (2009-2014, N=6,170)] were identified, with a mean age of nearly 70 years. For each Epoch group, point prevalence at baseline and 5-year HF incidence rate, comorbidities at baseline, and HF risk determinants (using Cox proportional hazards models) were calculated. Point prevalence of HF was 3.3% in Epoch 1990s, 6.0% in Epoch 2000s, and 4.8% in Epoch 2010s, with an increase from the 1990s to 2000s followed by a decline in the 2010s, yielding an overall statistically significant upward trend (p<0.001). 5-year incidence of HF per 1,000 person-years was 16.3 (95%CI: 15.0 to 17.8), 10.3 (95%CI: 9.2 to 11.4) and 7.9 (95%CI: 6.9 to 9.0) in respective epochs, with a downward trend. Hypertension was the most common comorbidity in HF patients, followed by dyslipidemia and kidney dysfunction. The association of hypertension and diabetes with risk of incident HF decreased over time. Coronary heart disease (CHD), atrial fibrillation (AF) and stroke all showed increasing hazard ratios across groups. The prevalence of HF increased during the past decades in a population-based setting, while HF incidence declined. Hypertension and diabetes tended to become less critical risk factors for new-onset HF nowadays, while CHD, AF, and stroke showed trends toward stronger associations with HF risk over time.
中文摘要:关于心力衰竭(HF)流行情况及其时间变化的信息有限。当前研究旨在报告鹿特丹研究过去三十年间的心力衰竭流行情况,涵盖患病率、发病率、合并症和风险决定因素。利用基于人群的鹿特丹队列数据,识别出三个年代组[1990年代组(1989—1993年,N=7,983)、2000年代组(1997—2001年,N=7,738)和2010年代组(2009—2014年,N=6,170)],平均年龄接近70岁。对每个年代组计算基线时点患病率和5年心力衰竭发病率、基线合并症以及心力衰竭风险决定因素(采用Cox比例风险模型)。心力衰竭时点患病率在1990年代组为3.3%,2000年代组为6.0%,2010年代组为4.8%,从1990年代到2000年代上升,随后在2010年代下降,总体呈统计学显著上升趋势(p<0.001)。各年代组每1,000人年的5年心力衰竭发病率分别为16.3(95%CI:15.0至17.8)、10.3(95%CI:9.2至11.4)和7.9(95%CI:6.9至9.0),呈下降趋势。高血压是心力衰竭患者最常见的合并症,其次是血脂异常和肾功能不全。高血压和糖尿病与新发心力衰竭风险的关联随时间减弱。冠心病(CHD)、心房颤动(AF)和卒中在各组中的风险比均呈上升。过去数十年间,在基于人群的环境中,心力衰竭患病率上升,而心力衰竭发病率下降。高血压和糖尿病如今趋于成为新发心力衰竭较不关键的风险因素,而冠心病、心房颤动和卒中与心力衰竭风险的关联随时间呈增强趋势。
Intravenous thrombolysis is a standard treatment for acute ischemic stroke but has traditionally been limited to 4.5 hours after symptom onset. This time-based restriction may exclude patients with salvageable brain tissue, especially those with wake-up or unknown-onset strokes. Multimodal imaging allows for the identification of viable penumbra beyond traditional treatment windows. This study compiles randomized evidence evaluating intravenous thrombolysis in imaging-selected patients treated after 4.5 hours. We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Cochrane Central were searched through February 2026 for randomized trials comparing intravenous thrombolysis (alteplase or tenecteplase) with best medical therapy in patients presenting beyond 4.5 hours or with wake-up/unknown-onset stroke selected by imaging. The primary outcome was excellent functional outcome at 90 days (modified Rankin Scale score 0-1). Secondary outcomes included functional independence (modified Rankin Scale score 0-2), symptomatic intracranial hemorrhage, and 90-day mortality. Fourteen trials involving 4192 participants were analyzed. Intravenous thrombolysis improved excellent functional outcomes (modified Rankin Scale score 0-1; risk ratio, 1.22 [95% CI, 1.16-1.29]) and functional independence (modified Rankin Scale score 0-2; risk ratio, 1.12 [95% CI, 1.06-1.18]). Both alteplase and tenecteplase contributed to these benefits. Thrombolysis increased the risk of symptomatic intracranial hemorrhage (risk ratio, 2.58 [95% CI, 1.58-4.22]) but did not significantly affect 90-day mortality (risk ratio, 1.15 [95% CI, 0.97-1.35]). In patients selected using advanced imaging, intravenous thrombolysis performed after 4.5 hours improves functional outcomes without increasing mortality, supporting a tissue-based rather than strictly time-based approach to treating acute ischemic stroke.
中文摘要:静脉溶栓是急性缺血性卒中的标准治疗,但传统上限于症状出现后4.5小时内。这一时间限制可能把仍有可挽救脑组织的患者排除在外,醒后卒中或发病时间不明的患者尤其如此。多模态影像能够在传统治疗时间窗之外识别存活的缺血半暗带。本研究汇总了影像筛选后超过4.5小时接受静脉溶栓患者的随机证据。我们按照PRISMA指南开展系统评价与荟萃分析。检索PubMed、Embase和Cochrane Central至2026年2月,纳入比较静脉溶栓(阿替普酶或替奈普酶)与最佳药物治疗的随机试验,对象为发病超过4.5小时或醒后卒中、发病时间不明并经影像筛选的患者。主要结局为90天良好功能结局(改良Rankin量表评分0–1)。次要结局包括功能独立(改良Rankin量表评分0–2)、症状性颅内出血和90天死亡率。共分析14项试验、4192例受试者。静脉溶栓改善了良好功能结局(改良Rankin量表评分0–1;风险比1.22[95% CI,1.16–1.29])和功能独立(改良Rankin量表评分0–2;风险比1.12[95% CI,1.06–1.18])。阿替普酶与替奈普酶均对这些获益有贡献。溶栓增加了症状性颅内出血风险(风险比2.58[95% CI,1.58–4.22]),对90天死亡率无显著影响(风险比1.15[95% CI,0.97–1.35])。在采用先进影像筛选的患者中,4.5小时后实施静脉溶栓可改善功能结局且不增加死亡率,支持以组织为基础的而非严格以时间为基础的急性缺血性卒中治疗思路。
OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85-1.44]; P=0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96-1.30]; P=0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93-1.13]; P=0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03-1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27-2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05686070.
中文摘要:OCEANIC-STROKE(XXX)研究显示,在非心源性缺血性卒中或高风险短暂性脑缺血发作患者中,在抗血小板治疗基础上加用asundexian可减少缺血性卒中,且未显著增加出血。本研究对出血类别、部位及关键亚组进行了分析。安全性人群中,12254例受试者至少接受1剂asundexian(n=6124)或安慰剂(n=6130)。出血按国际血栓与止血学会标准分为大出血、临床相关非大出血(CRNM)或轻微出血。治疗期间分析纳入至末次给药后2天的事件,并将死亡和永久停药作为竞争风险。大出血在asundexian组发生117例(1.9%),安慰剂组107例(1.7%)(病因特异性风险比[csHR] 1.10,95% CI 0.85-1.44;P=0.46)。大出血或CRNM出血分别发生339例(5.5%)和307例(5.0%)(csHR 1.12,95% CI 0.96-1.30;P=0.16),任何出血分别发生763例(12.5%)和752例(12.3%)(csHR 1.02,95% CI 0.93-1.13;P=0.65)。大出血及大出血或CRNM出血的治疗效应在预设亚组中一致,包括计划接受双联抗血小板治疗者。症状性颅内出血分别发生41例(0.7%)和36例(0.6%)。任何消化道出血分别发生186例(3.0%)和147例(2.4%)(csHR 1.28,95% CI 1.03-1.59),下消化道出血分别发生102例(1.7%)和59例(1.0%)(csHR 1.75,95% CI 1.27-2.41),主要为直肠出血。任何操作相关出血和任何黏膜出血均无显著差异。在抗血小板治疗基础上加用asundexian可减少缺血性卒中,且未显著增加大出血、大出血或CRNM出血或任何出血。asundexian组下消化道出血更常见,而大出血及大出血或CRNM出血的治疗效应在预设亚组中一致。URL: https://www.clinicaltrials.gov;唯一标识符:NCT05686070。
Gravitational gradients, ranging from the surface of the Earth (1 G) to the microgravity of spaceflight (0 G), including intermediate gravitational fields such as those on Mars (⅜ G), directly affect cardiovascular hemodynamics. We sought to track changes in cardiac structure and function over the course of long-duration spaceflight and compare them with responses to specific gravitational loads measured preflight and postflight in a uniquely simulated Martian gravitational load. We performed a prospective, within-subject, repeated-measures observational study of astronauts during flights to the International Space Station, with acquisition of echocardiographic variables during preflight supine rest and upright tilt at specific gravitational loads, including simulated Martian gravity (22° tilt; 0.38 G). Data were subsequently acquired during spaceflight onboard the International Space Station, upon landing on Earth, and after landing during exposure to simulated Martian gravity. Offline analyses of echocardiographic images were performed according to standardized methods, including myocardial deformation measurements. Thirteen astronauts (9 male) with a mean age of 49±4 years were included. The median spaceflight duration was 164 days (interquartile range, 126 to 169 days; median absolute deviation, 21 days). Significant reductions occurred in left ventricular (LV) end-diastolic volume, stroke volume, and myocardial deformation measures from preflight supine to early in-flight (14 days) measures in microgravity. These early in-flight values were similar in magnitude to those observed in the preflight upright Earth posture, with the exception of an increase in LV longitudinal strain magnitude (-14.5%±1.79% versus -16.9%±2.03%; P=0.006) and a reduction in LV global circumferential strain (-26.09%±1.76% versus -23.3%±3.22%; P=0.016). Throughout the subsequent duration of spaceflight, LV end-diastolic volume and LV stroke volume increased toward preflight supine values. After ≈6 months in space, when astronauts were exposed to simulated Martian gravity (⅜ G), no volumetric or hemodynamic measure evinced greater load or hemodynamic stress than upright posture on Earth before flight. In this small exploratory study, initial changes in LV chamber volumes, myocardial mechanics, cardiac output, and stroke volume with transition from Earth's gravitational loads to microgravity were transient and stabilized during flight. Given current countermeasures, prolonged spaceflight of up to 6 months does not result in large changes in cardiac structure or function within the context of normal posture variations on Earth. These adaptations generally return to baseline upon return to Earth, with no large changes in cardiac volumes or function relative to the upright posture on Earth in a simulated Martian gravity landing, suggesting that orthostatic intolerance may be unlikely to occur on Mars after a 6-month transport with appropriate exercise countermeasures.
中文摘要:重力梯度从地球表面(1 G)到航天飞行微重力(0 G),并包括火星等中间重力场(⅜ G),直接影响心血管血流动力学。我们试图追踪长期航天飞行期间心脏结构与功能的变化,并将其与飞行前和飞行后在独特模拟火星重力负荷下测得的特定重力负荷反应进行比较。我们对前往国际空间站的宇航员开展了前瞻性、受试者内、重复测量观察性研究,在飞行前仰卧静息和特定重力负荷下的直立倾斜过程中采集超声心动图变量,包括模拟火星重力(22°倾斜;0.38 G)。随后在国际空间站飞行期间、着陆地球时以及着陆后暴露于模拟火星重力期间采集数据。按照标准化方法对超声心动图图像进行离线分析,包括心肌形变测量。共纳入13名宇航员(9名男性),平均年龄49±4岁。航天飞行时间中位数为164天(四分位距126至169天;中位绝对偏差21天)。从飞行前仰卧到微重力飞行早期(14天)的测量,左心室舒张末期容积、每搏量和心肌形变指标出现显著降低。除左室纵向应变幅度增加(-14.5%±1.79% 对 -16.9%±2.03%;P=0.006)和左室整体周向应变降低(-26.09%±1.76% 对 -23.3%±3.22%;P=0.016)外,这些飞行早期数值的幅度与飞行前地球直立姿势下观察到的数值相似。在随后的航天飞行期间,左室舒张末期容积和左室每搏量向飞行前仰卧数值回升。在太空约6个月后,当宇航员暴露于模拟火星重力(⅜ G)时,没有任何容量或血流动力学指标显示出比飞行前地球直立姿势更大的负荷或血流动力学应激。在这项小型探索性研究中,左室腔容积、心肌力学、心输出量和每搏量随地球重力负荷向微重力转换的初始变化是短暂的,并在飞行期间稳定。在现有防护措施下,长达6个月的长期航天飞行不会在地球正常姿势变化范围内导致心脏结构或功能的大幅改变。这些适应在返回地球后总体恢复至基线;在模拟火星重力着陆时,相对于地球直立姿势,心脏容积或功能没有大幅改变,这提示在采取适当运动防护措施的情况下,经过6个月转运抵达火星后,直立不耐受或许不太可能发生。
Determining the source of thromboembolism in patients with acute ischemic stroke remains challenging because current diagnostic approaches rely largely on circumstantial and inferential associations rather than direct identification of the cause of stroke. Fluorine-18 GP1 ([18F]GP1) is a novel radiotracer that binds with high affinity and specificity to activated glycoprotein IIb/IIIa receptors on activated platelets. We aimed to determine whether hybrid [18F]GP1 positron emission tomography (PET) and computed tomography angiography could identify in vivo cardiovascular thromboembolism in patients with acute ischemic stroke and provide a mechanism-based assessment of stroke etiology. In a single-center prospective observational cohort study, 100 patients presenting with acute ischemic stroke underwent hybrid [18F]GP1 PET/computed tomography angiography within 21 days of symptom onset in addition to standard-of-care stroke investigations. Stroke etiology was classified using the causative classification system by an expert stroke physician blinded to [18F]GP1 PET findings. In parallel, [18F]GP1 PET/computed tomography angiography images were analyzed independently by readers who were blinded to all clinical data and causative classification system classification. We assessed whether [18F]GP1 PET/computed tomography angiography could identify the source of in vivo cardiovascular thromboembolism, influence stroke classification, and predict recurrent cerebrovascular events. Cardiovascular [18F]GP1 uptake indicative of thrombosis was identified in nearly two-thirds (n=63) of participants, changing stroke classification in over a quarter (n=26) of patients. In those with stroke of undetermined cause, the source of thrombus was identified in 18 of 41 (44%) participants, which included nonstenotic carotid atherothrombosis, native cardiac valve thrombosis, and paradoxical thromboembolism. During a median follow-up of 613 (interquartile interval, 251-788) days, recurrent stroke or transient ischemic attack occurred in 14 patients, 13 (93%) of whom had cardiovascular [18F]GP1 uptake at baseline. Cardiovascular [18F]GP1 uptake was associated with a 10.4-fold increased risk of recurrent events (95% CI, 1.35-79.40; P=0.024). Noninvasive thrombosis imaging is a novel technique that enables direct in vivo identification of thrombus formation and frequently reveals the source of thromboembolism in patients with acute ischemic stroke. This approach represents a shift from inference-based to mechanism-based stroke classification with potential implications for targeted prevention strategies and better patient outcomes. URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05636748.
中文摘要:确定急性缺血性卒中患者血栓栓塞来源仍具挑战,因为当前诊断方法很大程度上依赖间接和推断性关联,而非直接识别卒中病因。氟-18 GP1([18F]GP1)是一种新型放射性示踪剂,以高亲和力和特异性结合活化血小板上的活化糖蛋白IIb/IIIa受体。我们旨在确定[18F]GP1正电子发射断层扫描(PET)与计算机断层扫描血管造影的混合成像能否识别急性缺血性卒中患者体内心血管血栓栓塞,并提供基于机制的卒中病因评估。在一项单中心前瞻性观察性队列研究中,100例急性缺血性卒中患者在症状发作21天内接受混合[18F]GP1 PET/计算机断层扫描血管造影检查,同时接受标准卒中检查。卒中病因由对[18F]GP1 PET结果设盲的卒中专科医生使用病因分类系统进行分类。平行地,[18F]GP1 PET/计算机断层扫描血管造影图像由对所有临床数据和病因分类系统分类设盲的阅片者独立分析。我们评估[18F]GP1 PET/计算机断层扫描血管造影能否识别体内心血管血栓栓塞来源、影响卒中分类并预测复发性脑血管事件。近三分之二(n=63)参与者中发现提示血栓形成的心血管[18F]GP1摄取,超过四分之一(n=26)患者卒中分类因此改变。在病因未明卒中者中,41例中18例(44%)识别出血栓来源,包括非狭窄性颈动脉粥样硬化血栓形成、自体心脏瓣膜血栓形成和矛盾性血栓栓塞。中位随访613(四分位区间251-788)天期间,14例患者发生复发性卒中或短暂性脑缺血发作,其中13例(93%)基线时存在心血管[18F]GP1摄取。心血管[18F]GP1摄取与复发事件风险增加10.4倍相关(95% CI,1.35-79.40;P=0.024)。无创血栓成像是一种新技术,可在体内直接识别血栓形成,并常能揭示急性缺血性卒中患者血栓栓塞来源。该方法代表从基于推断的卒中分类转向基于机制的卒中分类,可能对靶向预防策略和改善患者结局产生影响。网址:https://www.clinicaltrials.gov;唯一标识符:NCT05636748。
The Lancet Diabetes and Endocrinology Commission recently proposed the new definition of preclinical and clinical obesity. Our study aimed to investigate the associations of the novel obesity classifications with incident cardiovascular disease (CVD). In 459 102 UK Biobank participants enrolled between 2006 and 2010, we applied the new definitions of clinical and preclinical obesity, based on the presence of excess adiposity with or without organ dysfunction, to assess their associations with incident CVD and its subtypes. Participants were further stratified into a seven-category classification integrating the Lancet framework with traditional body mass index (BMI) categories. Multivariable Cox regression estimated hazard ratios (HRs) and 95% confidence intervals (CI) for each obesity classification in relation to CVD risk. Over a median follow-up of 11.0 years, a total of 51 640 cases of CVD incidence were recorded. Compared with those with no obesity, individuals with preclinical obesity exhibited modestly elevated risks of CVD (HR 1.11, 95% CI 1.08-1.15), while clinical obesity was associated with substantially higher risks of total CVD (HR 1.77, 95% CI 1.72-1.82) and all subtypes, including coronary heart disease (CHD), stroke, and heart failure. Furthermore, newly diagnosed preclinical and clinical obesity with BMI below the conventional obesity threshold also had elevated incident CVD risk, with strongest association for CHD. The new framework advances CVD risk stratification beyond BMI alone, emphasizing the importance of incorporating excess body fat and functional health assessments into obesity diagnosis. Stronger associations with clinical obesity highlight its utility as a cumulative disease burden classifier, identifying individuals at higher cardiovascular risk.
中文摘要:《柳叶刀·糖尿病与内分泌学》委员会近期提出了临床前肥胖与临床肥胖的新定义。本研究旨在考察新的肥胖分类与心血管疾病(CVD)发病之间的关联。在2006至2010年纳入的459102名英国生物银行参与者中,我们依据是否存在过度脂肪蓄积并伴或不伴器官功能障碍,应用临床前肥胖和临床肥胖的新定义,评估其与CVD及其亚型发病的关联。参与者进一步按《柳叶刀》框架与传统的体重指数(BMI)分类整合为七类分类。多变量Cox回归估计各肥胖分类与CVD风险的风险比(HR)和95%置信区间(CI)。中位随访11.0年期间,共记录51640例CVD发病。与无肥胖者相比,临床前肥胖者的CVD风险轻度升高(HR 1.11,95% CI 1.08-1.15),临床肥胖与总CVD(HR 1.77,95% CI 1.72-1.82)及所有亚型(包括冠心病、卒中和心力衰竭)的更高风险相关。新诊断的临床前肥胖和临床肥胖者若BMI低于传统肥胖阈值,其CVD发病风险也升高,其中与冠心病的关联最强。新框架使CVD风险分层超越单纯BMI,强调将体脂过多和功能健康评估纳入肥胖诊断的重要性。临床肥胖与CVD的关联更强,提示其可作为累积疾病负担分类工具,识别心血管风险更高的个体。
Peak oxygen consumption (pVO2) has been widely recognized to identify potential pathophysiological mechanisms of exercise intolerance and to stratify risk in patients with heart failure (HF). To develop a non-exercise equation to estimate pVO2 (esVO2) and to determine its association with all-cause mortality. A total of 5176 HF patients (age 48 ± 17 years) who underwent a CPET for clinical reasons, and were followed between May 2011, and December 1, 2023. Clinical and historical variables and forced expiratory volume in 1-s (FEV1) were used in a stepwise multivariate regression analysis to predict pVO2 measured from CPET. Kaplan-Meier curves and Cox proportional hazards analyses were used to determine the association between esVO2 and all-cause mortality. The first esVO2 model was significantly associated with pVO2 (multiple R = 0.73, P < 0.001). Two other models considered gender separately (male: multiple R = 0.72, P < 0.001 and female (multiple R = 0.70, P < 0.001). A fourth model was proposed when spirometry is not available (age, BMI, resting SBP, HR and gender (multiple R = 0.69, P < 0.001)). The fifth proposed model included history of atrial fibrillation and previous stroke (multiple R = 0.70, P < 0.001). Kaplan-Meier survival curves differentiated patients according to esVO2 and pVO2 ≤ and > 14 mL/kg-1 per min-1. Univariate Cox proportional hazard analyses indicated significant prognostic value when esVO2 and pVO2 were ≤ 14 mL/kg-1 per min-1 (P = 0.001). Multivariable nonexercise models combining spirometry and/or clinical variables commonly obtained during a clinical assessment predict pVO2 reasonably accurately in HF.
中文摘要:峰值氧耗量(pVO2)已被广泛用于识别运动不耐受的潜在病理生理机制并对心衰患者进行风险分层。开发一个非运动方程估算pVO2(esVO2),并确定其与全因死亡的关系。共纳入5176例因临床原因接受CPET的心衰患者(年龄48±17岁),随访时间为2011年5月至2023年12月1日。采用临床与病史变量及第1秒用力呼气容积(FEV1),通过逐步多变量回归分析预测CPET测得的pVO2。用Kaplan-Meier曲线和Cox比例风险分析确定esVO2与全因死亡的关系。第一个esVO2模型与pVO2显著相关(多重R=0.73,P<0.001)。另外两个模型分别考虑性别(男性:多重R=0.72,P<0.001;女性:多重R=0.70,P<0.001)。当无肺功能测定时提出第四个模型(年龄、BMI、静息SBP、HR和性别,多重R=0.69,P<0.001)。第五个模型纳入房颤史和既往卒中史(多重R=0.70,P<0.001)。Kaplan-Meier生存曲线按esVO2和pVO2≤与>14 mL/kg-1 per min-1区分患者。单因素Cox比例风险分析显示,当esVO2和pVO2≤14 mL/kg-1 per min-1时具有显著预后价值(P=0.001)。结合肺功能测定和/或临床评估中常规获取的临床变量的多变量非运动模型能在心衰中较准确预测pVO2。
Radiation therapy (RT) is highly efficacious in treating thoracic malignancies. However, RT has been linked to potential cardiotoxicity. Yet, the long-term incidence, severity, and implications of HTN-development post-RT are unknown. Leveraging a large US-based Comprehensive-Cancer-Center-cohort of patients treated with thoracic-RT from 2007 to 2019, we included patients ≥18 years old with histologically confirmed esophageal or lung cancers. The primary outcome was incidence of incident/new or worsened HTN [systolic-blood-pressure-(SBP) ≥130 mmHg] after RT-initiation. The secondary outcomes were major-adverse-cardiac-events (MACE- heart-failure, myocardial-infarction, arrhythmia, stroke, and sudden-death), disease-progression, and overall-survival, by HTN-status. Differences in outcomes by HTN-status were also evaluated via landmark-analysis, excluding those with undiagnosed HTN. Observed new HTN rates were compared to Framingham-predicted-rates, and absolute-excess-risks were estimated. Multivariate regression was used to define the relation between clinical and RT measures and both new or worsened HTN-development and survival-outcomes. Overall, 439 RT-treated patients (238 esophageal; 201 lung; 66.7% male; mean age 63.6 years; 65% baseline HTN) were identified. Over a median follow-up of 23 months, 255 (58.1%) developed new or worsened HTN; median SBP increase of 7 mmHg. In landmark-analysis, the cumulative incidence of new or worsened HTN by 1-year was 48.0% and 63.4%, respectively. Using the JNC-8 cutoff of ≥140/90 mmHg, the new HTN rate was 21.6% at 1-year, translating to a 3.4-fold higher rate than the Framingham-predicted-rate (RR 3.37, P < 0.001). In multivariate regression, RT-dose was consistently associated with new or worsened HTN-development (P < 0.05); those with RT-induced-HTN saw improved progression-free-survival and overall-survival (HR 0.67 and 0.54, P < 0.01, respectively). Beyond traditional factors, only RT-dose is consistently associated with MACE (P < 0.05). No specific antihypertensive class prevented RT-related HTN. These data suggest that thoracic-RT increases early HTN risk.
中文摘要:放疗在胸部恶性肿瘤治疗中疗效显著。但放疗可能与潜在心脏毒性相关。放疗后高血压发生的长期发生率、严重程度及影响仍不清楚。研究利用美国大型综合癌症中心队列,纳入2007至2019年接受胸部放疗、年龄≥18岁、经组织学确诊的食管癌或肺癌患者。主要结局为放疗开始后新发或加重高血压(收缩压≥130 mmHg)的发生率。次要结局按高血压状态评估主要不良心脏事件(心力衰竭、心肌梗死、心律失常、卒中及猝死)、疾病进展和总生存。通过landmark分析排除未确诊高血压者,评估不同高血压状态下的结局差异。将观察到的新发高血压率与Framingham预测率比较,并估算绝对超额风险。多因素回归用于明确临床及放疗指标与新发或加重高血压及生存结局的关系。共识别439例接受放疗的患者(食管癌238例;肺癌201例;男性66.7%;平均年龄63.6岁;基线高血压65%)。中位随访23个月期间,255例(58.1%)出现新发或加重高血压;收缩压中位升高7 mmHg。landmark分析中,1年时新发或加重高血压的累积发生率分别为48.0%和63.4%。采用JNC-8界值≥140/90 mmHg时,1年新发高血压率为21.6%,为Framingham预测率的3.4倍(RR 3.37,P < 0.001)。多因素回归中,放疗剂量与新发或加重高血压持续相关(P < 0.05);出现放疗相关高血压者无进展生存和总生存改善(HR 0.67和0.54,P < 0.01)。除传统因素外,仅放疗剂量与MACE持续相关(P < 0.05)。未发现特定类别降压药可预防放疗相关高血压。这些数据提示胸部放疗增加早期高血压风险。
Global dementia incidence estimates are limited by underrepresentation of low- and middle-income countries and heterogeneous analytic methods. Due to these limitations, true understanding of the global dementia landscape remains incomplete. To identify dementia incidence rates by age and sex in various regions worldwide (high-income countries and low- and middle-income countries) where data on clinically based dementia diagnoses were available. Retrospective community-based cohorts from the Cohort Studies of Memory in an International Consortium (COSMIC); baseline recruitment commenced between January 1990 and December 2011 and follow-up data were collected through the end of 2021. Data were analyzed from June 2024 to June 2025. Eligible studies included longitudinal COSMIC cohort studies with a clinically based diagnosis of dementia. Individual participant-level data from 22 population-based longitudinal cohorts (N = 38 418) spanning 18 countries or territories across 6 continents were included. Data extraction and assessment of study quality and validity were conducted according to Meta-Analyses of Observational Studies in Epidemiology (MOOSE) guidelines. Individual participant-level data were meta-analyzed in a 2-step process using random intercepts for country and study at the global and regional levels and by country income level. For each study with a clinically based diagnosis, incidence rates for all-cause dementia were calculated and a 2-step meta-analysis was conducted. Using a person-years at risk framework with inverse-probability censoring weights and Poisson models, age- and sex-specific incidence were estimated and then standardized to the 2023 global age-sex population structure. Across 287 632 person-years at risk, 3001 participants developed dementia. Age- and sex-standardized incidence was 9.7 (95% CI, 7.89-11.97) per 1000 person-years at risk. Age-standardized incidence was higher in women than men (10.6; 95% CI, 8.61-13.11 vs 8.6; 95% CI, 6.94-10.72). Standardized incidence was higher in low- and middle-income countries (13.6; 95% CI, 9.67-19.24) than in high-income countries (8.3; 95% CI, 6.57-10.54). Applying age- and sex-specific rates to the projected 2050 population yielded a projected 24.7 million new cases, assuming constant incidence over time. The harmonized estimates presented in this study provide a comparable benchmark for global dementia incidence and inform planning for prevention, diagnosis, and memory-care services, particularly in underrepresented low- and middle-income country settings.
中文摘要:全球痴呆发病率估计受低收入和中等收入国家代表性不足及分析方法异质性限制,对全球痴呆格局的真实理解仍不完整。本研究旨在识别全球不同地区(高收入国家及低收入和中等收入国家)在可获得基于临床痴呆诊断数据时,按年龄和性别划分的痴呆发病率。研究纳入国际记忆联盟队列研究(COSMIC)中的回顾性社区队列,基线招募始于1990年1月至2011年12月,随访数据收集至2021年底,数据分析时间为2024年6月至2025年6月。合格研究为COSMIC中具有基于临床痴呆诊断的纵向队列。共纳入来自6大洲18个国家或地区的22个人群纵向队列的个体参与者数据(N=38418)。数据提取及研究质量和有效性评估依据观察性研究流行病学荟萃分析(MOOSE)指南进行。个体参与者数据采用两步法进行荟萃分析,在全球和地区层面以及按国家收入水平,对国家与研究设置随机截距。对每项具有基于临床诊断的研究计算全因痴呆发病率,并进行两步法荟萃分析。采用风险人年框架,结合逆概率删失权重和泊松模型估计年龄和性别特异性发病率,然后标准化至2023年全球年龄性别人口结构。在287632风险人年中,3001名参与者发生痴呆。年龄和性别标准化发病率为每1000风险人年9.7(95%CI,7.89-11.97)。女性年龄标准化发病率高于男性(10.6;95%CI,8.61-13.11 对 8.6;95%CI,6.94-10.72)。低收入和中等收入国家的标准化发病率(13.6;95%CI,9.67-19.24)高于高收入国家(8.3;95%CI,6.57-10.54)。将年龄和性别特异性发病率应用于2050年预测人口,假设发病率随时间保持恒定,预计将产生2470万新发病例。本研究提出的一致性估计为全球痴呆发病率提供了可比基准,并为预防、诊断和记忆照护服务规划提供信息,尤其是在代表性不足的低收入和中等收入国家环境中。
Current guidelines recommend targeting systolic blood pressure (SBP) below 130 mmHg in patients at high cardiovascular risk, including after acute coronary syndrome (ACS), although evidence specific to the post-ACS setting remains limited. We evaluated the prognostic value of SBP measured 1 year after ACS on subsequent cardiovascular outcomes. The ELIPS cohort prospectively enrolled ACS patients across four Swiss tertiary-care centers (2009-2017). Patients alive at 1 year with available SBP measurements were included. The association between SBP at 1 year and 3-point major adverse cardiovascular events (MACE; cardiovascular death, non-fatal stroke/transient ischemic attack, or non-fatal myocardial infarction) was modeled using restricted cubic splines, adjusted for age, sex, renal function, cardiovascular risk factors, index-event type, coronary revascularization, cardiac rehabilitation, heart-failure history, and antihypertensive medication classes. Among 2,074 patients (age 63±12 years; 82% male; 53% STEMI), 229 MACE events occurred over a median follow-up of 4.0 years (2.7 per 100 patient-years). The SBP-MACE relationship was nonlinear and J-shaped (P-non-linearity=0.007), with lowest risk between ∼130 and 140 mmHg (formally estimated nadir 138 mmHg [95%CI 116-152]). Above 140 mmHg, each 5-mmHg increase was associated with a borderline increase in MACE risk (adjusted HR 1.08; 95%CI 1.00-1.17). The pattern was broadly consistent across sex, age and hypertension status, with a possible interaction with diabetes that could not be excluded (P-interaction=0.08). In this large, predominantly male, well-characterized post-ACS cohort, SBP measured 1 year after ACS showed a J-shaped association with cardiovascular risk, with lowest risk at 130-140 mmHg.
中文摘要:现有指南建议对心血管高危人群(包括急性冠脉综合征后患者)将收缩压控制在130 mmHg以下,但针对急性冠脉综合征后这一特定情形的证据仍然有限。本研究评估急性冠脉综合征后1年时测得的收缩压对后续心血管结局的预后价值。ELIPS队列前瞻性纳入瑞士四家三级医疗中心的急性冠脉综合征患者(2009—2017年)。纳入1年时存活且具备收缩压测量值的患者。采用限制性立方样条模型分析1年时收缩压与3点主要不良心血管事件(MACE,即心血管死亡、非致死性卒中或短暂性脑缺血发作、非致死性心肌梗死)之间的关联,并校正年龄、性别、肾功能、心血管危险因素、索引事件类型、冠状动脉血运重建、心脏康复、心力衰竭病史及各类降压药物。在2074例患者中(年龄63±12岁;男性82%;ST段抬高型心肌梗死53%),中位随访4.0年期间共发生229例MACE事件(每100患者年2.7例)。收缩压与MACE的关系呈非线性且为J型(非线性P=0.007),风险最低处约在130至140 mmHg之间(正式估计的最低点为138 mmHg,95%CI 116-152)。收缩压高于140 mmHg时,每升高5 mmHg与MACE风险呈边缘性升高相关(校正HR 1.08;95%CI 1.00-1.17)。该模式在性别、年龄和高血压状态各亚组中大体一致,与糖尿病的交互作用可能存在,但无法排除(交互作用P=0.08)。在这一以男性为主、特征描述充分的大型急性冠脉综合征后队列中,急性冠脉综合征后1年测得的收缩压与心血管风险呈J型关联,风险最低处位于130-140 mmHg。
Adherence with a holistic or integrated care management of atrial fibrillation (AF) based on the AF better care (ABC) pathway has been associated with improved clinical outcomes. Two prospective randomized trials (mAFA and MIRACLE-AF) have evaluated this approach. The multicentre mAFA-II trial delivered the ABC pathway via mobile health using an mAFA App, while the MIRACLE-AF trial relied on village doctors supported by telehealth in rural communities. We conducted a pooled analysis of individual participant data to assess the overall efficacy of ABC pathway-based management in patients with AF. We combined patient-level data from the mAFA-II and MIRACLE-AF trials. The primary endpoint was defined as a composite of all-cause mortality, ischaemic stroke, haemorrhagic stroke, heart failure (HF), acute coronary syndrome (ACS), and major bleeding events. The secondary endpoints included individual components and two grouped outcomes: all stroke and HF/ACS. A one-stage marginal Cox proportional hazards model stratified by trial and with robust standard errors clustered at the site level was used, with adjustment for CHA2DS2-VASc and other clinically relevant baseline variables. Cumulative event rates were estimated using Kaplan-Meier methods. Subgroup and sensitivity analyses were conducted to assess the robustness of the findings. Between-trial heterogeneity was further explored using a two-stage approach, incorporating trial-level effect estimates and inverse-variance weighting. We studied 4363 patients with AF [mean age 70.3 (SD 12.8) years; 60.5% male]. During 0.8 [SD 0.4] years of follow-up, the primary endpoint occurred in 329 (7.5%). Kaplan-Meier curves demonstrated lower cumulative incidence of events in the intervention group. On multivariable mixed-effects Cox models, the intervention group demonstrated a significantly lower risk of the primary endpoint compared to the control group (adjusted hazard ratio: 0.72; 95% confidence interval: 0.56-0.93). Subgroup analyses suggested potential effect modification, whereas sensitivity analyses consistently supported the primary findings. A two-stage analysis showed directionally consistent effects across trials for the primary endpoint. In this pooled individual participant data from two prospective randomized trials, ABC pathway-based integrated care was associated with improved clinical outcomes in patients with AF vs. usual care, with the observed benefit primarily driven by reductions in HF/ACS-related events rather than classical AF-specific outcomes, supporting further implementation studies and context-specific adoption in clinical practice.
中文摘要:基于房颤优化照护(ABC)路径的整体化或整合式房颤管理,其依从性与临床结局改善相关。mAFA与MIRACLE-AF两项前瞻性随机试验对该策略进行了评价。多中心mAFA-II试验通过移动健康手段、借助mAFA应用程序实施ABC路径,MIRACLE-AF试验则依托农村社区中由远程医疗支持的乡村医生。本研究对个体参与者数据进行汇总分析,评估基于ABC路径的管理对房颤患者的总体疗效。研究合并mAFA-II与MIRACLE-AF试验的患者层面数据。主要终点为全因死亡、缺血性卒中、出血性卒中、心力衰竭、急性冠脉综合征及大出血事件的复合终点。次要终点包括各单项事件及两个组合结局:全部卒中与心衰/急性冠脉综合征。采用按试验分层的单阶段边际Cox比例风险模型,并以中心层面聚类的稳健标准误,校正CHA2DS2-VASc及其他临床相关基线变量。累积事件率用Kaplan-Meier法估计。进行亚组与敏感性分析以评估结果的稳健性。试验间异质性另以两阶段方法探讨,纳入试验水平效应估计并按逆方差加权。共纳入4363例房颤患者,平均年龄70.3岁(标准差12.8),男性占60.5%。随访0.8年(标准差0.4)期间,329例(7.5%)发生主要终点事件。Kaplan-Meier曲线显示干预组事件累积发生率更低。多变量混合效应Cox模型显示,与对照组相比干预组主要终点风险显著降低(校正风险比0.72;95%置信区间0.56-0.93)。亚组分析提示可能存在效应修饰,敏感性分析一致支持主要结果。两阶段分析显示各试验主要终点效应方向一致。在这项来自两项前瞻性随机试验的汇总个体参与者数据中,基于ABC路径的整合式管理与常规照护相比与房颤患者临床结局改善相关,观察到的获益主要由心衰/急性冠脉综合征相关事件的减少所驱动,而非经典房颤特异性结局,支持进一步开展实施性研究并在临床实践中因地制宜地采用。
基础研究 (13篇)
Ischemic stroke (IS), caused by cerebral blood vessel occlusion, leads to ischemia, hypoxia, and irreversible brain tissue damage. Current treatments primarily rely on thrombolytic agents like alteplase, urokinase, and streptokinase for rapid reperfusion. However, these therapies are limited by narrow therapeutic windows, rapid clearance, poor blood-brain barrier (BBB) penetration, off-target effects, and the complex ischemic microenvironment. These have led to increased interest in nanomaterial-based platforms to improve the precision and efficacy of IS treatment. The IS microenvironment, characterized by oxidative stress, inflammation, ionic imbalance, acidosis, and BBB disruption, provides valuable cues for designing responsive nanomaterials. Nanomaterials engineered to respond to reactive oxygen species, pH, enzymes, light, ultrasound, or magnetic fields can enable targeted drug delivery, controlled release, and multi-modal interventions, enhancing therapeutic precision. This review discusses the IS microenvironment, limitations of traditional therapies, recent advances in intelligent nanomaterials for IS treatment, and the major barriers that currently limit clinical translation.
中文摘要:缺血性卒中(IS)由脑血管闭塞引起,导致缺血、缺氧和不可逆脑组织损伤。当前治疗主要依赖阿替普酶、尿激酶和链激酶等溶栓药物实现快速再灌注。这些疗法受限于治疗时间窗窄、清除快、血脑屏障(BBB)穿透差、脱靶效应以及复杂的缺血微环境。上述局限促使研究者关注基于纳米材料的平台,以提高IS治疗的精准性和疗效。IS微环境以氧化应激、炎症、离子失衡、酸中毒和BBB破坏为特征,为设计响应性纳米材料提供了有价值的线索。经工程化设计、可对活性氧、pH、酶、光、超声或磁场作出响应的纳米材料,能够实现靶向药物递送、控释和多模式干预,提升治疗精准度。讨论内容包括IS微环境、传统疗法的局限、智能纳米材料用于IS治疗的最新进展,以及当前限制临床转化的主要障碍。
Distinguishing resident microglia from infiltrating myeloid cells in stroke scRNA-seq data remains challenging due to shared myeloid markers; SALL1 shows greater specificity for microglia compared with commonly used markers (e.g. TMEM119, CX3CR1, P2RY12), and combining SALL1 with these commonly used markers improves the ability to distinguish microglia from infiltrating myeloid populations in stroke‑associated scRNA‑seq datasets.
中文摘要:在卒中单细胞RNA测序数据中,由于髓系标志物存在重叠,区分驻留小胶质细胞与浸润性髓系细胞仍有困难;与常用标志物(如TMEM119、CX3CR1、P2RY12)相比,SALL1对小胶质细胞的特异性更高,将SALL1与这些常用标志物联合使用,可提高在卒中相关scRNA-seq数据集中区分小胶质细胞与浸润性髓系细胞群体的能力。
Gamma oscillations are fundamental for cognitive processing, but the cellular and circuit dynamics that generate them remain poorly defined. Establishing a method for simultaneous calcium imaging and electrocorticography recordings in awake mice, we found that spontaneous gamma oscillations are accompanied by dynamic transitions between parvalbumin (PV) interneuron states. Rather than acting as a uniformly synchronized population, PV interneurons showed sequential recruitment, transient inactivation, and frequent transitions between activity states, indicating the formation of dynamic functional networks. In J20 Alzheimer's disease mice, these state transitions became dysregulated, leading to abnormal PV recruitment, impaired coupling between PV activity and gamma oscillations, and network hyperexcitability. Increasing interneuron excitability through expression of the voltage-gated sodium channel Nav1.1 restored PV cell dynamics, gamma oscillations, and network stability. These findings reveal dynamic PV cell states as an organizing feature of gamma oscillations and identify their disruption as a circuit mechanism of network dysfunction in Alzheimer's disease.
中文摘要:伽马振荡是认知加工的基础,但产生这些振荡的细胞和环路动力学仍不清楚。我们建立了一种在清醒小鼠中同步进行钙成像和皮层脑电记录的方法,发现自发伽马振荡伴随小白蛋白(PV)中间神经元状态之间的动态转换。PV中间神经元并非作为均匀同步的群体活动,而是表现出顺序募集、短暂失活以及活动状态间的频繁转换,提示动态功能网络的形成。在J20阿尔茨海默病小鼠中,这些状态转换失调,导致PV募集异常、PV活动与伽马振荡的耦联受损以及网络高兴奋性。通过表达电压门控钠通道Nav1.1提高中间神经元兴奋性,可恢复PV细胞动力学、伽马振荡和网络稳定性。这些发现揭示动态PV细胞状态是伽马振荡的组织特征,并确定其破坏是阿尔茨海默病网络功能障碍的一种环路机制。
Supramolecular engineering using cyclodextrins offers an effective strategy to enhance the solubility and efficacy of hydrophobic bioactive molecules. In this study, we have developed a rutin (RTN) inclusion complex (IC) incorporated pullulan (PL)-based nanofibrous system for the delivery of RTN, improving its solubility and efficacy. The IC was prepared via host-guest complexation of methyl-β-cyclodextrin (M-β-CD) with RTN, as confirmed by nuclear magnetic resonance (NMR) spectroscopy. Further, the developed IC was incorporated into the PL matrix to fabricate fast-dissolving electrospun nanofibers (PL/IC-NF). Solid state characterization using Fourier transform infrared (FTIR), powder X-ray diffraction (P-XRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA) demonstrated intermolecular interactions, reduced crystallinity, and incorporation of IC within PL nanofibrous matrix. The scanning electron microscopy (SEM) revealed uniform and bead-free fibers with smooth morphology. The IC incorporation remarkably enhanced the aqueous solubility of RTN (∼46-fold) and enabled its rapid disintegration (∼3 s). The in vivo evaluation in a zebrafish intracerebral hemorrhage (ICH) model demonstrated reduced hemorrhagic severity, oxidative stress, apoptosis, and inflammation, while protecting neuronal damage. Our study demonstrated that integrating supramolecular ICs with electrospun nanofibers offers an effective strategy to enhance the efficacy of poorly soluble nutraceuticals and represents a promising strategy for ICH intervention.
中文摘要:利用环糊精的超分子工程是提高疏水性活性分子溶解度和功效的有效策略。本研究构建了载芦丁(RTN)包合物(IC)的普鲁兰多糖(PL)纳米纤维系统,用于递送RTN并改善其溶解度和功效。通过甲基-β-环糊精(M-β-CD)与RTN的主客体络合制备IC,并经核磁共振(NMR)确认。随后将IC掺入PL基质,制备速溶静电纺纳米纤维(PL/IC-NF)。采用傅里叶变换红外光谱(FTIR)、粉末X射线衍射(P-XRD)、差示扫描量热法(DSC)和热重分析(TGA)进行固态表征,显示分子间相互作用、结晶度降低以及IC被包载于PL纳米纤维基质中。扫描电子显微镜(SEM)显示纤维均匀、无串珠且形貌光滑。IC的引入使RTN的水溶解度提高约46倍,并实现约3秒的快速崩解。在斑马鱼脑出血(ICH)模型中的体内评价显示,出血严重程度、氧化应激、细胞凋亡和炎症均降低,同时保护神经元免受损伤。研究表明,将超分子包合物与静电纺纳米纤维结合,是提高难溶性营养保健品功效的有效策略,也为ICH干预提供了有前景的思路。
Small cell lung cancer (SCLC) remains one of the most lethal malignancies, with a 5-year survival of <10% despite advances in treatment. Seizure-related gene 6 (SEZ6), a type I transmembrane protein preferentially expressed in neuroendocrine tumors, has recently emerged as a promising therapeutic target, supported by clinical activity of SEZ6-targeted antibody-drug conjugates in relapsed SCLC. In this study, we developed and evaluated a humanized anti-SEZ6 monoclonal antibody for SEZ6-targeted positron emission tomography imaging and α-particle radioimmunotherapy. Immunohistochemistry of patient tissues confirmed strong, stage-independent SEZ6 expression. Cell-based studies demonstrated high SEZ6 receptor densities, supporting high-affinity antibody binding and rapid receptor-mediated internalization. [89Zr]Zr-DFO-SEZ6-Ab administered at low antibody mass exhibited rapid hepatosplenic clearance with minimal tumor uptake despite high intratumoral levels. This pattern was consistent with active ectodomain shedding and local accumulation of soluble antigen within the tumor microenvironment, creating an extracellular antigen sink and limiting effective target engagement. Increasing the antibody mass overcame this barrier, dramatically increasing tumor uptake in xenografts. Treatment with [225Ac]Ac-Macropa-SEZ6-Ab induced complete tumor regression, whereas coadministration of the ATR inhibitor berzosertib enhanced efficacy at lower radioactivity doses without added toxicity. Together, these findings identify tumor-localized SEZ6 shedding as a biological barrier to SEZ6-targeted therapy, define dosing strategies to overcome it, and demonstrate potent antitumor activity of SEZ6-directed α-particle radioimmunotherapy in SCLC. Dosing strategies that overcome antigen sink effects induced by a tumor-localized ectodomain shedding enable SEZ6-based imaging and theranostics in small cell lung cancer.
中文摘要:小细胞肺癌(SCLC)仍是最致命的恶性肿瘤之一,尽管治疗已有进展,5年生存率仍低于10%。癫痫相关基因6(SEZ6)是一种优先在神经内分泌肿瘤中表达的I型跨膜蛋白,SEZ6靶向抗体偶联药物在复发SCLC中显示出临床活性,使SEZ6近期成为有前景的治疗靶点。本研究开发并评价了一种人源化抗SEZ6单克隆抗体,用于SEZ6靶向正电子发射断层成像和α粒子放射免疫治疗。患者组织免疫组化证实SEZ6强表达,且表达与分期无关。细胞研究显示SEZ6受体密度高,支持高亲和力抗体结合和快速受体介导的内化。低抗体质量给予[89Zr]Zr-DFO-SEZ6-Ab时,药物快速经肝脾清除,尽管瘤内抗原水平高,肿瘤摄取仍很低。这一模式与活跃的胞外域脱落及可溶性抗原在肿瘤微环境中局部积聚一致,形成细胞外抗原池,限制有效的靶点结合。提高抗体质量可克服这一屏障,在异种移植瘤中大幅提高肿瘤摄取。以[225Ac]Ac-Macropa-SEZ6-Ab治疗可诱导肿瘤完全消退,联合ATR抑制剂berzosertib可在较低放射性剂量下增强疗效,且未增加毒性。这些结果将肿瘤局部SEZ6脱落确定为SEZ6靶向治疗的生物学屏障,明确了克服该屏障的给药策略,并证明SEZ6导向的α粒子放射免疫治疗在SCLC中具有强效抗肿瘤活性。克服肿瘤局部胞外域脱落所致抗原池效应的给药策略,使基于SEZ6的成像和诊疗一体化在小细胞肺癌中得以实现。
Single-cell resolution spatial transcriptomics provides a great opportunity to explore the complex cellular contents in different tissues. Here we introduce SpatialZoomer, a spectral graph-based method that applies a set of low-pass filters to efficiently extract spatial molecular features from spatial transcriptomics data at multiple resolutions or scales, including the single cell scale, the niche scale with dozens of closely interacting cells and the domain scale with spatially organized cell contents. The corresponding critical scales can be automatically identified by partitioning a cross-scale similarity map. Results show that SpatialZoomer can identify disease-progression signals at specific scales in Alzheimer's disease and spatial context-dependent cell subtypes in tumour microenvironment. The extracted multi-scale features also uncovered spatially heterogeneous niches in cancer. SpatialZoomer achieves comparable or superior performance to existing methods for single-scale tasks, and it also has the advantages of high computational efficiency and low hardware requirements.
中文摘要:单细胞分辨率空间转录组为探索不同组织中的复杂细胞内容提供了重要机会。SpatialZoomer 是一种基于谱图的方法,对空间转录组数据应用一组低通滤波器,在多种分辨率或尺度上高效提取空间分子特征,包括单细胞尺度、由数十个紧密相互作用细胞构成的生态位尺度,以及具有空间组织化细胞内容的结构域尺度。通过划分跨尺度相似性图,可自动识别相应的关键尺度。结果表明,SpatialZoomer 能在阿尔茨海默病中识别特定尺度上的疾病进展信号,也能在肿瘤微环境中识别空间背景依赖的细胞亚型。提取的多尺度特征还揭示了癌症中空间异质的生态位。对于单尺度任务,SpatialZoomer 的性能与现有方法相当或更优,并具有计算效率高、硬件要求低的优势。
The midbrain dopamine system is integral to movement, reward, and motivation, and its dysfunction underlies a range of brain disorders. Age is a primary risk factor for many of these disorders, yet systematic analysis of how the dopamine system changes during healthy aging remains relatively understudied. In this review, we first examine the impact of healthy aging on the dopamine system across sexes and species, including flies, mice, rats, and humans. We next consider the neuroadaptive mechanisms that sustain dopamine neuron function with age. Finally, we contrast the molecular mechanisms of age-related neurodegenerative diseases with those of healthy aging, exploring the possibility that loss of neuroadaptive reserve drives dopamine neurodegeneration. Elucidating these neuroadaptive mechanisms could offer a path toward preserving dopamine neuron function across the lifespan and potentially preventing age-related neurodegeneration.
中文摘要:中脑多巴胺系统参与运动、奖赏和动机,其功能异常是多种脑部疾病的基础。年龄是许多此类疾病的主要风险因素,但健康衰老过程中多巴胺系统如何变化,系统的分析仍相对不足。本综述首先考察健康衰老对多巴胺系统的影响,涵盖不同性别与物种,包括果蝇、小鼠、大鼠和人类。随后讨论随年龄增长维持多巴胺神经元功能的神经适应机制。最后将年龄相关神经退行性疾病的分子机制与健康衰老的分子机制进行对比,探讨神经适应储备的丧失是否驱动多巴胺神经退行性变。阐明这些神经适应机制,或可为在整个生命周期中维持多巴胺神经元功能、并可能预防年龄相关神经退行性变提供途径。
Systematic molecular characterization of human induced pluripotent stem cell (iPSC) lines carrying disease-associated mutations is needed to distinguish disease-related biology from variation in cell state, genomic integrity, and genome-editing history, yet such systematic characterization is uncommon. Here, we profiled 85 human iPSC lines carrying MAPT mutations and isogenic controls using whole-genome sequencing, long-read sequencing of the MAPT locus, bulk and single-cell RNA sequencing, and DNA methylation arrays. Single-cell analyses identified four reproducible iPSC states and candidate surface markers for their isolation. Whole-genome sequencing revealed unintended editing events and recurrent 20q11.21 duplications, which were associated with increased ID1 expression and impaired cortical organoid patterning. Transcriptomic analyses identified pathways associated with organoid quality and changes linked to clonal selection and editing, underscoring the need to use unconverted lines as isogenic controls. By providing an in-depth genomic characterization of MAPT iPSCs, this dataset serves as a proof of principle to enhance iPSC utility in biological research.
中文摘要:对携带疾病相关突变的人诱导多能干细胞(iPSC)系进行系统分子表征,有助于区分疾病相关生物学与细胞状态、基因组完整性和基因组编辑历史带来的变异,但这类系统表征并不常见。我们利用全基因组测序、MAPT位点长读长测序、批量与单细胞RNA测序以及DNA甲基化芯片,对85株携带MAPT突变的人iPSC系及其同基因对照进行了分析。单细胞分析识别出四种可重复的iPSC状态及用于分离这些状态的候选表面标志物。全基因组测序发现非预期编辑事件和反复出现的20q11.21重复,这些改变与ID1表达升高及皮质类器官图式形成受损相关。转录组分析识别出与类器官质量相关的通路,以及克隆选择和编辑带来的变化,说明需要使用未转化细胞系作为同基因对照。该数据集对MAPT iPSC进行了深入的基因组表征,可作为原理验证,提升iPSC在生物学研究中的应用价值。
Autoimmune diseases are characterized by loss of immune tolerance and substantial heterogeneity across patients, tissues, and disease stages. Although bulk transcriptomic studies have identified important inflammatory pathways, they cannot directly resolve rare, transitional, and tissue-contextualized cell states that may be relevant to disease mechanisms and therapeutic response. Single-cell RNA sequencing (scRNA-seq) enables transcriptomic profiling at cellular resolution, while complementary multimodal, receptor-repertoire, epigenomic, and spatial approaches can link cellular states to protein phenotype, clonal architecture, regulatory programs, and tissue context. This review critically examines recent single-cell studies in rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, type 1 diabetes, and multiple sclerosis. Rather than providing a descriptive catalogue of published studies, we assess the strength of available evidence by distinguishing independently replicated findings from observations supported by limited studies, and cross-sectional associations from longitudinal, treatment-response, and functional evidence. Across the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain. We evaluate the translational potential of scRNA-seq for biomarker discovery, patient stratification, and treatment response prediction, while considering evidence from related tissue-based molecular stratification approaches, including the R4RA randomized trial in rheumatoid arthritis. R4RA provides prospective randomized evidence that synovial molecular features can enrich for differential therapeutic responses, but its use of bulk synovial transcriptomics and histopathology does not constitute prospective validation of single-cell-derived biomarkers. We further highlight cohort biases, reproducibility challenges, dissociation artifacts, computational ambiguity, and privacy concerns that constrain immediate clinical implementation. Together, these advances position single-cell profiling as a mechanistic discovery platform with substantial translational promise, contingent on standardization, validation across diverse cohorts, and integration with functional perturbation approaches.
中文摘要:自身免疫病的特征是免疫耐受丧失,以及患者、组织和疾病阶段之间的显著异质性。bulk转录组研究已识别出重要炎症通路,但无法直接解析可能与疾病机制和治疗反应相关的稀有、过渡性及组织情境化的细胞状态。单细胞RNA测序(scRNA-seq)可在细胞分辨率上进行转录组分析,而互补的多模态、受体库、表观基因组和空间方法可将细胞状态与蛋白表型、克隆结构、调控程序及组织背景联系起来。本综述批判性审视类风湿关节炎、系统性红斑狼疮与狼疮肾炎、1型糖尿病和多发性硬化中的近期单细胞研究。本文并不提供已发表研究的描述性目录,而是通过区分独立重复的发现与仅有有限研究支持的观察、横断面关联与纵向、治疗反应及功能证据,评估现有证据的强度。在所选的疾病中,研究反复报告涉及干扰素信号、趋化因子介导的免疫募集和基质与免疫细胞相互作用的炎症程序;然而,细胞状态和调控网络层面趋同的证据仍然有限,共享特征在多大程度上代表共同致病机制而非炎症背景仍不确定。我们评估scRNA-seq在生物标志物发现、患者分层和治疗反应预测方面的转化潜力,同时考虑来自相关组织分子分层方法的证据,包括类风湿关节炎中的R4RA随机试验。R4RA提供了前瞻性随机证据,表明滑膜分子特征可富集差异治疗反应,但其使用bulk滑膜转录组学和组织病理学并不构成对单细胞来源生物标志物的前瞻性验证。我们进一步强调限制即刻临床实施的队列偏倚、可重复性挑战、解离伪影、计算模糊性和隐私问题。这些进展共同将单细胞分析定位为具有重大转化前景的机制发现平台,其前提是标准化、在多样队列中的验证以及与功能扰动方法的整合。
With the global aging population, age-related neurodegenerative diseases and cerebrovascular diseases have become major public health challenges. As a modifiable lifestyle strategy, dietary intervention shows significant potential in delaying brain aging and reducing the risk of neurodegenerative and cerebrovascular diseases. Caloric restriction (CR) and dietary restriction (DR), two important nutritional intervention approaches, exhibit substantial neuroprotective potential through multiple mechanisms. This review systematically summarizes the mechanisms of CR and DR in brain aging and related diseases, focusing on: (1) modulating gene expression and epigenetic modifications; (2) regulating proteostasis and autophagy; (3) inhibiting neuroinflammation to delay inflammaging; (4) improving mitochondrial function and oxidative homeostasis; and (5) optimizing nutrient-sensing pathways and metabolism. Additionally, this review discusses the mechanistic evidence of CR and DR in disease models such as Alzheimer's Disease (AD), Parkinson's Disease (PD), stroke, and Vascular Dementia (VaD). Despite promising preclinical findings, their clinical translation faces challenges including individual variability, safety concerns, and uncertainty regarding mechanism prioritization. Future research should focus on conducting more high-quality clinical trials, integrating multi-omics technologies with precision nutrition strategies to promote the practical application of CR and DR in advancing healthy brain aging.
中文摘要:随着全球人口老龄化,年龄相关神经退行性疾病和脑血管疾病已成为重大公共卫生挑战。饮食干预作为一种可改变的生活方式策略,在延缓脑老化及降低神经退行性疾病和脑血管疾病风险方面显示出显著潜力。热量限制(CR)和饮食限制(DR)是两种重要的营养干预方式,通过多种机制表现出较强的神经保护潜力。本综述系统总结CR和DR在脑老化及相关疾病中的作用机制,重点包括:(1)调节基因表达与表观遗传修饰;(2)调控蛋白质稳态与自噬;(3)抑制神经炎症以延缓炎性衰老;(4)改善线粒体功能与氧化稳态;(5)优化营养感应通路与代谢。综述还讨论CR和DR在阿尔茨海默病(AD)、帕金森病(PD)、卒中和血管性痴呆(VaD)等疾病模型中的机制证据。尽管临床前研究结果令人关注,其临床转化仍面临个体差异、安全性问题以及机制优先次序不确定等挑战。未来研究应开展更高质量临床试验,整合多组学技术与精准营养策略,推动CR和DR在促进健康脑老化中的实际应用。
Cerebral small vessel disease (cSVD) is a leading cause of stroke and vascular cognitive impairment, yet the cellular mechanisms underlying microvascular dysfunction in human disease remain incompletely understood. In particular, the relationship between pericyte alterations and endothelial activation, two key features of blood-brain barrier dysfunction, remains unresolved. Here, we performed a quantitative single-vessel analysis of the human cortical microvasculature across increasing cSVD severity and ageing. Using multiplex immunohistochemistry combined with spectral unmixing and automated image analysis, we analysed 11,409 microvascular fragments from post-mortem brain tissue derived from 20 cases. Endothelial cells, pericytes, and endothelial activation were assessed using PECAM-1, PDGFRβ, and VCAM-1, respectively. Microvascular density and diameter differed between cortical grey matter and the underlying white matter, with white matter vessels being less dense and wider in controls. While vessel diameter remained stable across cSVD severity groups, microvascular density increased with cSVD severity and age in the white matter. At the molecular level, PDGFRβ signal decreased markedly with increasing cSVD severity, consistent with reduced pericyte coverage. This reduction was observed in both grey and white matter and correlated with disease severity and age. Notably, intermediate severity groups displayed marked heterogeneity, with vessels exhibiting either preserved or markedly reduced PDGFRβ signal. In parallel, endothelial markers PECAM-1 and VCAM-1 increased significantly with disease severity, reflecting endothelial activation. Unsupervised Gaussian mixture clustering of marker expression identified three vascular states characterised by (i) preserved PDGFRβ signal with low endothelial activation, (ii) reduced PDGFRβ signal without endothelial activation, and (iii) reduced PDGFRβ signal combined with endothelial activation. These clusters broadly aligned with neuropathological severity but revealed heterogeneity not captured by post-mortem diagnosis alone. Together, these findings suggest that pericyte alterations and endothelial activation are partially dissociated processes in human cSVD and identify distinct microvascular phenotypes across disease severity. These cross-sectional observations provide a framework for future longitudinal and experimental studies to determine their temporal and mechanistic relationships.
中文摘要:脑小血管病(cSVD)是卒中和血管性认知障碍的主要原因,但人类疾病中微血管功能障碍的细胞机制仍未完全明确。周细胞改变与内皮激活是血脑屏障功能障碍的两个关键特征,二者之间的关系尚未解决。我们对随cSVD严重程度和年龄增加的人皮质微血管进行了单血管定量分析。采用多重免疫组化结合光谱解混和自动图像分析,分析了来自20例死后脑组织的11,409个微血管片段。分别用PECAM-1、PDGFRβ和VCAM-1评估内皮细胞、周细胞和内皮激活。皮质灰质与下方白质的微血管密度和直径不同,对照中白质血管密度较低且较宽。血管直径在各cSVD严重程度组间保持稳定,而白质微血管密度随cSVD严重程度和年龄增加。分子层面,PDGFRβ信号随cSVD严重程度增加明显下降,与周细胞覆盖减少一致。这种下降见于灰质和白质,并与疾病严重程度和年龄相关。中间严重程度组表现出明显异质性,血管或保留PDGFRβ信号,或明显降低。与此同时,内皮标志物PECAM-1和VCAM-1随疾病严重程度显著增加,反映内皮激活。对标志物表达进行无监督高斯混合聚类,识别出三种血管状态:(i)PDGFRβ信号保留且内皮激活低;(ii)PDGFRβ信号降低但无内皮激活;(iii)PDGFRβ信号降低并伴内皮激活。这些聚类大体与神经病理严重程度一致,但揭示了仅凭死后诊断未能捕捉的异质性。这些发现提示,在人cSVD中周细胞改变与内皮激活是部分分离的过程,并识别出随疾病严重程度不同的微血管表型。这些横断面观察为未来纵向和实验研究确定其时间与机制关系提供了框架。
The lack of approaches to produce interleukin (IL)-10-producing B cells at high frequency has hampered mechanistic investigation into the generation, fate, and activity of these regulatory cells. We screened pharmacological compounds for their ability to induce IL-10 expression in B cells. One compound, N6, promoted stable IL-10 expression in >95% of B cells. Transfer of IL-10+ B cells induced remission of experimental autoimmune encephalomyelitis. N6-induced B cells accumulated in the central nervous system (CNS) and differentiated into IL-10+ plasma cells, promoting transcriptional and phenotypic changes in myeloid cells within the CNS. The therapeutic effect of IL-10+ B cell transfer was abrogated in mice lacking IL-10 receptor expression in long-lived myeloid cells, pointing to microglia as targets of B cell-derived IL-10. Importantly, an N6 analog corrected defective IL-10 expression in B cells from multiple sclerosis patients. Our findings establish a pharmacological strategy to generate IL-10+ B cells with therapeutic potential and identify microglia as critical targets for intercepting neuroinflammatory disease progression.
中文摘要:目前尚无高频制备产白细胞介素10(IL-10)B细胞的方法,这限制了对这类调节性细胞产生、命运与活性的机制研究。我们筛选了可诱导B细胞表达IL-10的药理化合物,其中化合物N6使超过95%的B细胞稳定表达IL-10。转输IL-10阳性B细胞可诱导实验性自身免疫性脑脊髓炎缓解。N6诱导的B细胞在中枢神经系统内积聚并分化为IL-10阳性浆细胞,促使中枢神经系统内髓系细胞发生转录与表型改变。在长寿命髓系细胞缺乏IL-10受体表达的小鼠中,IL-10阳性B细胞转输的治疗效应消失,提示小胶质细胞是B细胞来源IL-10的靶细胞。一种N6类似物可纠正多发性硬化患者B细胞中IL-10表达的缺陷。这些结果建立了一种生成具有治疗潜力IL-10阳性B细胞的药理策略,并确定小胶质细胞是阻断神经炎症性疾病进展的关键靶点。
Cerebral cavernous malformations (CCMs) are cerebrovascular diseases characterized by vascular lesions of the central nervous system (CNS) that can result in epileptic seizures, headaches, focal neurologic deficits (FNDs), and hemorrhagic stroke. Germline and somatic loss-of-function (LOF) mutations in one of the three established CCM-associated genes, namely CCM1 (or krev interaction trapped protein 1, KRIT1), CCM2, and CCM3 (or programmed cell death 10, PDCD10), which have been validated as core drivers of CCM pathogenesis and progression. Over the past few decades, a substantially improved understanding of the hallmarks and molecular basis of CCMs has been achieved. Key pathological hallmarks include but are not limited to excessive angiogenesis, vascular leakage, endothelial-mesenchymal transition (EndMT), defective autophagy, inflammation and immune response, oxidative stress, influenced gut microbiome and altered brain vascular microenvironment. These hallmarks are orchestrated by dysregulated signaling cascades, notably MEKK3-KLF2/4, PI3K-mTOR, and RhoA-ROCK, which integrate genetic, inflammatory, and hemodynamic cues. Concurrently, sophisticated neuroimaging (MRI with SWI/QSM) and genetic testing now enable precise diagnosis and risk stratification. Although surgical resection remains the mainstay for accessible symptomatic lesions, a wave of mechanism‑based pharmacological candidates has shown promising efficacy in preclinical models, and several have advanced to early‑phase clinical trials. This review summarizes the current understanding of CCM epidemiology, molecular pathogenesis, diagnosis and therapy, highlighting how the evolving multi‑hit concept and the dissection of downstream signaling are paving the way towards personalized management of this complicated vascular disease.
中文摘要:脑海绵状血管畸形(CCMs)是中枢神经系统血管病变所致脑血管疾病,可引起癫痫发作、头痛、局灶性神经功能缺损(FNDs)和出血性卒中。CCM1(krev interaction trapped protein 1,KRIT1)、CCM2和CCM3(programmed cell death 10,PDCD10)三个已确立的CCM相关基因中任一基因的胚系与体细胞功能丧失(LOF)突变,已被证实是CCM发病和进展的核心驱动因素。过去数十年对CCM标志性特征和分子基础的认识显著提升。关键病理标志包括但不限于过度血管生成、血管渗漏、内皮-间质转化(EndMT)、自噬缺陷、炎症与免疫反应、氧化应激、受影响的肠道微生物组以及改变的脑血管微环境。这些标志由失调的信号级联协调,尤其是MEKK3-KLF2/4、PI3K-mTOR和RhoA-ROCK,它们整合遗传、炎症和血流动力学线索。同时,先进神经影像(MRI结合SWI/QSM)和基因检测使精确诊断与风险分层成为可能。手术切除仍是可及症状性病变的主要手段,一批基于机制的候选药物在临床前模型中显示出有希望的疗效,其中几种已进入早期临床试验。综述总结CCM流行病学、分子发病机制、诊断和治疗的最新认识,强调不断演化的多次打击概念和对下游信号通路的剖析如何为这种复杂血管疾病的个体化管理铺路。
2痴呆与认知障碍 (17篇)
临床研究 (3篇)
Microglial dysfunction is increasingly implicated in Alzheimer's disease (AD) pathogenesis, with loss-of-function variants in the microglial receptor TREM2 as major risk factors for late-onset AD. We report VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages the transmembrane domains of TREM2 and its adaptor DAP12 to promote higher-order receptor complex formation and downstream signaling. VG-3927 and tool compound VG-3909 exhibited (sub)nanomolar potency, cooperated with endogenous ligands including amyloid-β (Aβ), and restored signaling in disease-associated TREM2 variants. In human iPSC-derived neuron-microglia-astrocyte cultures, VG-3927 reduced inflammatory cytokines and markers of neuronal damage. In 5xFAD amyloidosis mice expressing the common variant of hTREM2 (5xFAD;hTREM2CV), VG-3909 induced neuroprotective transcriptional reprogramming of microglia, particularly in the plaque niche; enhanced Aβ phagocytosis; and boosted brain glucose metabolism. By contrast, a TREM2 agonist antibody, which may be sequestered by soluble TREM2 (sTREM2), failed to engage plaque microglia. In a first-in-human, randomized, double-blind, placebo-controlled phase 1 trial (NCT06343636, n = 115), VG-3927 was well tolerated across single and multiple ascending doses of up to 140 milligrams. Pharmacokinetics supported once-daily dosing with high CNS penetration (CSF-to-unbound plasma ratio of 0.91). VG-3927 induced dose-dependent reductions in CSF sTREM2, a biomarker of target engagement, consistent across healthy and elderly participants and participants with AD, supporting further clinical development in AD under the new designation SAR448851.
中文摘要:小胶质细胞功能障碍日益被认为参与阿尔茨海默病(AD)发病,小胶质细胞受体TREM2的功能缺失变异是晚发型AD的主要风险因素。VG-3927是一种口服、可透过中枢神经系统的小分子TREM2激动剂,作用于TREM2及其衔接蛋白DAP12的跨膜结构域,促进高阶受体复合物形成和下游信号传导。VG-3927与工具化合物VG-3909表现出(亚)纳摩尔级效价,可与包括β淀粉样蛋白(Aβ)在内的内源性配体协同,并恢复疾病相关TREM2变异体的信号传导。在人iPSC来源的神经元-小胶质细胞-星形胶质细胞培养体系中,VG-3927减少炎症细胞因子和神经元损伤标志物。在表达人TREM2常见变异的5xFAD淀粉样变小鼠(5xFAD;hTREM2CV)中,VG-3909诱导小胶质细胞神经保护性转录重编程,尤其在斑块微环境;增强Aβ吞噬;提高脑葡萄糖代谢。相比之下,一种可能被可溶性TREM2(sTREM2)隔离的TREM2激动剂抗体未能作用于斑块相关小胶质细胞。在一项首次人体、随机、双盲、安慰剂对照1期试验(NCT06343636,n=115)中,VG-3927在单次和多次递增给药至140毫克范围内耐受良好。药代动力学支持每日一次给药,中枢神经系统穿透性高(脑脊液与未结合血浆比值0.91)。VG-3927诱导脑脊液sTREM2剂量依赖性下降,该指标为靶点结合生物标志物,在健康人、老年参与者和AD参与者中结果一致,支持以新代号SAR448851在AD中进一步临床开发。
DNA methylation (DNAm) plays a critical role in Alzheimer's disease (AD). Previous epigenome-wide association studies using 450K arrays captured limited CpG coverage and often focused on a single neuropathological measure. Here we profiled DNAm in 1,250 postmortem prefrontal cortex samples from the Rush Alzheimer's Disease cohorts using the Infinium MethylationEPIC v2 array (~930,000 CpGs) and performed epigenome-wide association studies of multiple neuropathologic measures, including AD diagnosis, amyloid-β and tau tangles. We identified 107 differentially methylated probes associated with AD neuropathology, 38 of which were replicated in an independent cohort (n = 139). DNAm also partially mediated the effect of APOE genotype on AD diagnosis (proportion mediated: 8.6%, P = 2 × 10-6). Moreover, 39 identified genes (for example, RIN3, LGMN, LHPP) were differentially expressed across major brain cell types, including neurons and astrocytes. These findings expand the epigenetic landscape of AD neuropathology and reveal DNAm as a mediator of APOE-related genetic risk.
中文摘要:DNA甲基化(DNAm)在阿尔茨海默病(AD)中起关键作用。既往使用450K芯片的表观全基因组关联研究覆盖的CpG位点有限,且常只关注单一神经病理指标。本研究用Infinium MethylationEPIC v2芯片(约930,000个CpG)对Rush阿尔茨海默病队列的1,250份死后前额叶皮层样本进行DNAm谱分析,并对包括AD诊断、β-淀粉样蛋白和tau缠结在内的多项神经病理指标开展表观全基因组关联研究。我们识别出107个与AD神经病理相关的差异甲基化探针,其中38个在独立队列(n=139)中得到重复。DNAm还部分介导了APOE基因型对AD诊断的影响(介导比例8.6%,P=2×10-6)。39个已识别基因(例如RIN3、LGMN、LHPP)在包括神经元和星形胶质细胞的主要脑细胞类型间存在差异表达。这些发现拓展了AD神经病理的表观遗传图谱,并揭示DNAm是APOE相关遗传风险的介导因素。
In trials targeting preclinical Alzheimer disease (AD), defined as amyloid pathology without cognitive symptoms, racial and ethnic differences in plasma phosphorylated tau 217 percentage (%p-tau217) may influence screening eligibility. To characterize racial and ethnic differences in %p-tau217 and determine whether associations between %p-tau217, cognition, and amyloid positron emission tomography (PET) differ across groups. This was a cross-sectional analysis of AHEAD 3-45 screening participants conducted from July 2020 to October 2024 at 106 sites across 4 world regions. Adults aged 55 to 80 years with %p-tau217 measured before medical and cognitive exclusions (N = 15 612) were included. Self-reported race (Asian, Black, and White) and ethnicity (Hispanic and non-Hispanic) and apolipoprotein E ε4 (APOE ε4) carrier status. %p-tau217 levels and associations of %p-tau217 with Preclinical Alzheimer Cognitive Composite 5 (PACC5) score and amyloid PET were evaluated across racial and ethnic groups using multivariable linear regression. Among 15 612 participants, the mean (SD) age was 68.4 (6.2) years; 9941 (63.7%) were female and 5755 (36.9%) were APOE ε4 carriers. %p-tau217 levels were lower among Asian, Black, and Hispanic participants than among White and non-Hispanic participants. APOE ε4 status was associated with higher %p-tau217 across all groups. The association between APOE ε4 status and %p-tau217 differed by race (APOE ε4 × race: F2,14 973 = 10.06; P < .001) and ethnicity (APOE ε4 × ethnicity: β, 0.042; 95% CI, 0.017 to 0.067; P = .005) (Asian: β, 0.05; 95% CI, 0.02 to 0.08; P = .01; Black: β, 0.05; 95% CI, 0.03 to 0.08; P = .002; Hispanic: β, 0.04; 95% CI, 0.02 to 0.07; P = .005). The %p-tau217-PACC5 association showed no pairwise differences across racial groups but differed by ethnicity (β, -0.53; 95% CI, -0.85 to -0.21; P = .008) and APOE ε4 × ethnicity (β, 0.78; 95% CI, 0.26 to 1.30; P = .02). The %p-tau217-PET association showed no significant pairwise differences across racial groups but differed by ethnicity (β, -6.30; 95% CI, -9.10 to -3.51; P < .001) and APOE ε4 × ethnicity (β, 7.12; 95% CI, 2.52 to 11.73; P = .01). In this cross-sectional study, plasma %p-tau217 varied across racial and ethnic groups. Consistent %p-tau217-PACC5 score and %p-tau217-PET associations across racial groups support plasma-based screening before PET confirmation, while ethnicity-related findings warrant further investigation.
中文摘要:在针对临床前阿尔茨海默病(AD,即存在淀粉样蛋白病理但无认知症状)的试验中,血浆磷酸化tau 217百分比(%p-tau217)的种族与族裔差异可能影响筛查入组的资格。本研究旨在刻画%p-tau217的种族与族裔差异,并判断%p-tau217与认知、淀粉样蛋白正电子发射断层扫描(PET)之间的关联是否在不同人群中存在差别。研究为AHEAD 3-45筛查受试者的横断面分析,2020年7月至2024年10月在4个世界区域的106个中心开展。纳入55至80岁、在医学与认知排除标准实施前已测定%p-tau217的成年人(N=15612)。变量包括自我报告的种族(亚裔、黑人、白人)与族裔(西班牙裔与非西班牙裔)以及载脂蛋白E ε4(APOE ε4)携带状态。采用多变量线性回归在各种族与族裔组中评估%p-tau217水平,以及%p-tau217与临床前阿尔茨海默病认知复合量表5(PACC5)评分和淀粉样蛋白PET的关联。15612名受试者平均(SD)年龄为68.4(6.2)岁,女性9941人(63.7%),APOE ε4携带者5755人(36.9%)。亚裔、黑人和西班牙裔受试者的%p-tau217水平低于白人和非西班牙裔受试者。APOE ε4状态在所有组中均与较高的%p-tau217相关。APOE ε4状态与%p-tau217的关联存在种族差异(APOE ε4×种族:F2,14973=10.06;P<.001)和族裔差异(APOE ε4×族裔:β=0.042;95%CI 0.017~0.067;P=.005)(亚裔:β=0.05;95%CI 0.02~0.08;P=.01;黑人:β=0.05;95%CI 0.03~0.08;P=.002;西班牙裔:β=0.04;95%CI 0.02~0.07;P=.005)。%p-tau217与PACC5的关联在各种族组之间无两两差异,但存在族裔差异(β=-0.53;95%CI -0.85~-0.21;P=.008)及APOE ε4×族裔交互(β=0.78;95%CI 0.26~1.30;P=.02)。%p-tau217与PET的关联在各种族组之间无显著两两差异,但存在族裔差异(β=-6.30;95%CI -9.10~-3.51;P<.001)及APOE ε4×族裔交互(β=7.12;95%CI 2.52~11.73;P=.01)。在这项横断面研究中,血浆%p-tau217在不同种族与族裔组之间存在差异。%p-tau217与PACC5评分、%p-tau217与PET的关联在各种族组中保持一致,支持在PET确认之前先行基于血浆的筛查;与族裔相关的发现有待进一步研究。
基础研究 (14篇)
Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no effective cure, characterized by the cerebral parenchymal and vascular accumulation of aggregated amyloid-β (Aβ) and hyperphosphorylated tau. Cerebrovascular and mitochondria dysfunction are early causal events in the progression of AD. Previous studies support that inhibiting carbonic anhydrases (CAs) may prevent mitochondrial and cerebrovascular dysfunction in AD models. Here, we selectively target the mitochondrial CA isoform CA-VB by pharmacological and genetic manipulation in human cerebral microvascular endothelial cells (hCMEC), and we confirm the protective effects of the CA-V inhibitor in AD mice. CA-V inhibition and CA-VB KO prevent Aβ induced mitochondria-mediated endothelial apoptosis, loss of barrier resistance, and hCMEC inflammatory activation. Strikingly, CA-V inhibition also mitigates caspase activation and endothelial cell activation in the brains of 3xTg AD mice, resulting in preserved memory function. Our results demonstrate that selective CA-V inhibition is an effective and promising strategy against AD-mediated cerebrovascular pathology, neuroinflammation and cognitive impairment.
中文摘要:阿尔茨海默病(AD)是一种缺乏有效治疗手段的毁灭性神经退行性疾病,特征为聚集的β-淀粉样蛋白(Aβ)和过度磷酸化tau在脑实质与血管中积聚。脑血管和线粒体功能障碍是AD进展中的早期因果事件。既往研究支持抑制碳酸酐酶(CAs)可能预防AD模型中的线粒体和脑血管功能障碍。通过药物和遗传操作在人脑微血管内皮细胞(hCMEC)中选择性靶向线粒体CA亚型CA-VB,并在AD小鼠中证实CA-V抑制剂的保护作用。抑制CA-V及敲除CA-VB可阻止Aβ诱导的线粒体介导内皮细胞凋亡、屏障电阻丧失以及hCMEC炎症激活。CA-V抑制还减轻3xTg AD小鼠脑内caspase激活和内皮细胞活化,从而保留记忆功能。结果说明选择性抑制CA-V是应对AD相关脑血管病理、神经炎症和认知损害的有效且有前景的策略。
Cognitive reserve theory posits that compensatory mechanisms during aging stave off cognitive decline and lower risk for Alzheimer's disease. Here, in a screen for hippocampal dentate granule cell (DGC) synapse loss-induced factors in mice, we identified a secreted phospholipase, Pla2g2f, whose expression increases in DGCs during aging and is associated with cognitive resilience in humans. Pla2g2f deletion in DGCs exacerbates aging-associated pathophysiological changes, including synapse loss, inflammatory microglia, reactive astrogliosis, impaired neurogenesis, lipid dysregulation, lipid droplet accumulation and hippocampal-dependent memory loss. Conversely, boosting Pla2g2f in DGCs during aging is sufficient to prevent these pathophysiological alterations in hippocampal-cortical circuits, protect memory and prophylactically modify trajectory of cognitive decline. Mutagenesis of the catalytic site of PLA2G2F prevented lipid droplet mobilization and reduction of reactive gliosis and inflammatory microglia. Neuronal PLA2G2F mediates intercellular signaling to decrease lipid droplet and cholesterol ester load in human induced pluripotent stem cell-derived microglia. Our findings implicate PLA2G2F as a compensatory neuroprotective broadcast signal that maintains lipid homeostasis to counteract aging-associated cognitive decline.
中文摘要:认知储备理论认为,衰老过程中的代偿机制可延缓认知衰退并降低阿尔茨海默病风险。我们在小鼠中筛选海马齿状回颗粒细胞(DGC)突触丢失诱导因子时,鉴定出一种分泌型磷脂酶 Pla2g2f;其在小鼠 DGC 中的表达随衰老升高,并与人类的认知韧性相关。在 DGC 中敲除 Pla2g2f 会加重衰老相关病理生理改变,包括突触丢失、炎症性小胶质细胞、反应性星形胶质细胞增生、神经发生受损、脂质失调、脂滴积聚以及海马依赖的记忆丧失。相反,衰老过程中增强 DGC 中的 Pla2g2f 足以阻止海马-皮层环路中的这些病理生理改变,保护记忆,并预防性地改变认知衰退轨迹。PLA2G2F 催化位点突变可阻止脂滴动员以及反应性胶质增生和炎症性小胶质细胞的减少。神经元 PLA2G2F 介导细胞间信号传递,降低人诱导多能干细胞来源小胶质细胞中的脂滴和胆固醇酯负荷。这些发现提示 PLA2G2F 作为一种代偿性神经保护广播信号,通过维持脂质稳态来对抗衰老相关认知衰退。
Cerebrospinal fluid (CSF)-adjacent brain areas are especially vulnerable to diffuse degeneration in multiple sclerosis (MS). Surface-in gradients arising from CSF-borne cytotoxic factors have been proposed to predict disease relapses independent of white matter lesions. Yet, whether such factors disrupt ependymal cells to penetrate the ventricular border in MS remains unknown. Here, using ultra-high-field magnetic resonance imaging-guided histology, electron microscopy and single-nucleus multiomics, we found that ependymal pathology correlates with periventricular gradients and involves an immune-reactive state marked by transporter and junctional protein dysregulation. We further defined the gene regulatory networks underpinning the MS ependymal state and predicted ligands known to be enriched in MS CSF that could drive the emergence of this state. One of the candidates, IFNγ, increased murine ependymal permeability in vivo, indicating that CSF ligands can modulate ependymal function and regional inflammation. These findings identify CSF-driven ependymal dysfunction as a contributor to periventricular pathology in MS.
中文摘要:多发性硬化中脑室周围梯度病理与室管膜反应性及细胞黏附破坏相关。脑脊液邻近脑区在多发性硬化(MS)中尤其易发生弥漫性退变。由脑脊液携带的细胞毒性因素引起的表面向内梯度已被提出可独立于白质病灶预测疾病复发。然而,这些因素在MS中是否破坏室管膜细胞以穿透脑室边界仍不清楚。我们利用超高场磁共振成像引导的组织学、电子显微镜和单核多组学发现,室管膜病理与脑室周围梯度相关,并涉及以转运蛋白和连接蛋白失调为标志的免疫反应状态。我们进一步确定了支撑MS室管膜状态的基因调控网络,并预测了在MS脑脊液中富集、可能驱动该状态出现的配体。候选之一IFNγ在体内增加了小鼠室管膜通透性,表明脑脊液配体可调节室管膜功能和区域炎症。这些发现将脑脊液驱动的室管膜功能障碍确定为MS脑室周围病理的一个促成因素。
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder lacking curative therapies, with ApoE4 as the strongest genetic risk factor driving lipid dyshomeostasis and neuronal damage in the central nervous system. Lipid rafts, cholesterol- and sphingolipid-rich membrane microdomains, govern key neuronal signalling, and dysfunction of these microdomains mediates the progression of preclinical pathological lesions in ApoE4 carriers. Dietary docosahexaenoic acid (DHA) is widely reported to mitigate brain lipid disorders, yet how DHA remodels subfractions of lipid raft and non-raft membrane domains to rescue ApoE4-related energy metabolism disorder remains unclear. Most existing studies have only quantified total brain lipids without distinguishing membrane subdomains, and few characterized the liver-brain metabolic axis underlying ApoE4-associated neurodegeneration. We constructed female ApoE3/3 and ApoE4/4 knock-in mice with 6- and 12-month DHA dietary interventions, combining behavioral, histological, lipidomic and proteomic assays to characterize genotype-specific lipid remodelling and downstream mitochondrial changes. Here we show that ApoE4 mice develop severe hepatic steatosis, neuroinflammation and lipid raft rigidification characterized by elevated sulfatides and ceramides levels, DHA upregulates Lpin1, Atgl and nSMase2 while suppressing Acer3 and Sgms2, thereby rebalancing lipids raft and restoring mitochondrial bioenergetics. Our work resolves raft and non-raft lipid profiles in ApoE humanized mice, and links peripheral hepatic metabolic disturbances to cerebral membrane microdomain dysfunction. These multi-omics mechanistic findings advance genotype-specific preventive nutritional strategies for ApoE4 carriers and reveal potential subcellular lipid targets for early AD intervention.
中文摘要:阿尔茨海默病(AD)是不可逆的神经退行性疾病,缺乏治愈手段,ApoE4是中枢神经系统脂质稳态失衡和神经元损伤的最强遗传风险因素。脂筏是富含胆固醇和鞘脂的膜微结构域,调控关键神经元信号,这些微结构域功能异常介导ApoE4携带者临床前病理病变进展。膳食二十二碳六烯酸(DHA)被广泛报道可缓解脑脂质紊乱,但DHA如何重塑脂筏与非脂筏膜结构域亚组分以挽救ApoE4相关能量代谢紊乱仍不清楚。现有研究大多只定量全脑脂质,未区分膜亚结构域,少数研究刻画了ApoE4相关神经退行性变背后的肝-脑代谢轴。我们构建雌性ApoE3/3与ApoE4/4敲入小鼠,分别进行6个月和12个月DHA膳食干预,结合行为学、组织学、脂质组学和蛋白质组学检测,刻画基因型特异性脂质重塑及下游线粒体变化。结果显示,ApoE4小鼠出现严重肝脂肪变性、神经炎症和脂筏僵硬,表现为硫脂和神经酰胺水平升高;DHA上调Lpin1、Atgl和nSMase2,抑制Acer3和Sgms2,从而再平衡脂筏脂质并恢复线粒体生物能量学。我们的工作解析了ApoE人源化小鼠脂筏与非脂筏脂质谱,将外周肝脏代谢紊乱与脑膜微结构域功能障碍联系起来。这些多组学机制发现推进了针对ApoE4携带者的基因型特异性预防营养策略,并揭示了可用于早期AD干预的潜在亚细胞脂质靶点。
Glucagon-like peptide-1 (GLP-1) is primarily known for its role in glucose homeostasis and food intake control, and GLP-1 analogs (either as monotherapy or dual agonists) are commonly used for type 2 diabetes and obesity treatment in humans. Beyond these functions, the GLP-1 receptor (GLP-1R) is widely expressed throughout the brain, including in the hippocampus (HPC) and interconnected regions that contribute to learning and memory processes. Here we review emerging evidence supporting a role for GLP-1 signaling in promoting learning and memory function, particularly in dementia and other conditions that manifest with HPC dysfunction. Evidence is synthesized from preclinical rodent models revealing that GLP-1 analog treatment improves deficits in memory function and HPC neuronal signaling processes in various models of dementia, aging, and metabolic disruption. While findings from human clinical trials and meta-analyses also show promise for GLP-1 analog-based treatment for memory disorders, results thus far are mixed, with many studies underpowered and/or lacking comprehensive memory evaluation. We describe several distinct yet non-mutually exclusive neurobiological mechanisms by which GLP-1R signaling can enhance memory, including blood-brain barrier penetration and direct action on HPC GLP-1Rs, improved peripheral and central insulin sensitivity, vagus nerve GLP-1R activation, and peripheral metabolic and inflammatory improvements. We conclude by emphasizing important considerations for future clinical trials for GLP-1 analogs in the treatment of Alzheimer's disease and other memory disorders, including focusing on metabolically vulnerable individuals, stratifying results by cardiovascular and metabolic status, and leveraging existing GLP-1 analogs and drug delivery approaches toward maximizing bioavailability and brain penetrance.
中文摘要:胰高血糖素样肽-1(GLP-1)最为人知的作用是参与血糖稳态和摄食控制,GLP-1类似物(单药或双激动剂)常用于人类2型糖尿病和肥胖治疗。除这些功能外,GLP-1受体(GLP-1R)广泛表达于脑内,包括海马(HPC)及与学习和记忆过程相关的相互连接区域。本综述汇总支持GLP-1信号促进学习和记忆功能的新近证据,尤其是在痴呆及表现为HPC功能障碍的其他疾病中。证据来自临床前啮齿动物模型,显示GLP-1类似物治疗可改善多种痴呆、衰老和代谢紊乱模型中的记忆功能缺陷及HPC神经元信号过程。人类临床试验和荟萃分析的结果也显示GLP-1类似物治疗记忆障碍具有前景,但迄今结果不一致,许多研究把握度不足和/或缺乏全面的记忆评估。文中描述GLP-1R信号增强记忆的若干不同但并非互斥的神经生物学机制,包括穿透血脑屏障并直接作用于HPC的GLP-1R、改善外周和中枢胰岛素敏感性、激活迷走神经GLP-1R,以及改善外周代谢和炎症。最后强调未来GLP-1类似物治疗阿尔茨海默病和其他记忆障碍临床试验的重要考虑,包括关注代谢脆弱个体、按心血管和代谢状态分层结果,并利用现有GLP-1类似物和药物递送方法以最大化生物利用度和脑内穿透。
TNF-α (Tumor Necrosis Factor) is a proinflammatory cytokine that amplifies inflammatory response and promotes leukocyte recruitment. TNF-α is primarily produced by activated macrophages, among others, in response to infection, inflammation, or tissue damage. Given its central role in normal and abnormal immune responses, it is the target of several therapeutics, such as adalimumab and etanercept. TNF-α is also a prognostic and diagnostic biomarker associated with rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, several kidney diseases, cancers, type 2 diabetes, sepsis, and others. Because TNF-α levels change dynamically during inflammatory responses, tools capable of sensitive and spatially resolved detection could enable improved monitoring of immune activity and disease progression. Single-walled carbon nanotubes (SWCNT) are cylindrical carbon lattices that emit distinct near-infrared bandgap photoluminescence. In this work, we evaluated three aptamer-based sensor constructs, plus an additional two iterations of one aptamer sequence, and two antibody-based sensor constructs for TNF-α that use SWCNT near-infrared photoluminescence signal transduction. Several, but not all, of these aptamer and antibody-based sensors sensitively and selectively detected TNF-α in human and bovine serum in a physiologically relevant range, and we found that their sensing was impacted by both passivation and incorporating an exogenous quencher onto the aptamer sequence. This study highlights the importance and challenges of translating previously-validated molecular recognition elements to new detection conditions, in this case on the surface of SWCNT and in challenging serum conditions. It also validated a lead sensor, the VR11-SWCNT aptamer construct with or without quencher chemistry and with surface passivation, that builds upon constructs that failed in serum. These results demonstrate a strategy toward synthesis of nanoscale optical sensors capable of detecting TNF-α. We anticipate that the sensors evaluated here will have utility in both the diagnosis and study of inflammation-driven chronic disease, while the sensor assessment framework will help drive the broader field of molecularly specific diagnostics.
中文摘要:TNF-α(肿瘤坏死因子)是一种促炎细胞因子,可放大炎症反应并促进白细胞募集。TNF-α主要由活化巨噬细胞等产生,以响应感染、炎症或组织损伤。鉴于其在正常和异常免疫反应中的核心作用,它已成为多种治疗药物的靶点,如阿达木单抗和依那西普。TNF-α也是与类风湿关节炎、阿尔茨海默病、多发性硬化、多种肾脏疾病、癌症、2型糖尿病、脓毒症等相关的预后和诊断生物标志物。由于TNF-α水平在炎症反应中动态变化,具备灵敏且空间分辨检测能力的工具可改善对免疫活动和疾病进展的监测。单壁碳纳米管(SWCNT)是圆柱形碳晶格,可发射独特的近红外带隙光致发光。我们评估了三种基于适配体的传感器构建体,外加对一条适配体序列的两种额外迭代,以及两种基于抗体的TNF-α传感器构建体,这些传感器均利用SWCNT近红外光致发光信号转导。这些适配体和抗体传感器中有几种(并非全部)在生理相关范围内于人和牛血清中灵敏、特异地检测到TNF-α;我们发现其传感受到表面钝化以及在适配体序列上引入外源淬灭剂的影响。这项研究凸显了将此前验证的分子识别元件转化到新的检测条件时所面临的重要性和挑战,此处的新条件为SWCNT表面和复杂的血清环境。该研究还验证了一种先导传感器,即VR11-SWCNT适配体构建体,其带有或不带有淬灭剂化学修饰并经过表面钝化,基于在血清中失效的构建体发展而来。这些结果展示了一种合成可检测TNF-α的纳米级光学传感器的策略。我们预期,此处评估的传感器将在炎症驱动慢性病的诊断和研究中发挥作用,而传感器评估框架将有助于推动更广泛的分子特异性诊断领域。
Alzheimer's disease (AD) and related dementias (ADRDs) remain incurable, partly due to their complex and poorly understood pathogenic mechanisms. Loss of vacuolar protein sorting-associated protein 35 (VPS35), a core component of the retromer complex, has been implicated in AD and ADRDs. While Vps35 deficiency is known to increase amyloidogenesis by regulating its cargo proteins, such as APP and BACE1, the precise mechanism by which VPS35 dysfunction leads to cognitive impairment remains elusive. While neuronal VPS35 regulates trafficking and functions of multiple synaptic membrane proteins, such as postsynaptic glutamatergic and GABAnergic receptors and pre-synaptic vesicle protein SV2A, and Levetiracetam (LEV), an antiepileptic drug that improves cognition, interacts with the SV2A, exactly how LEV enhances cognition is still a matter of debate. Given the abundant expression of VPS35 in pyramidal excitatory neurons, we generated a conditional knockout mouse model with Vps35 deletion from postnatal glutamatergic excitatory neurons (Vps35CaMKIIα) and characterized its phenotypes using a combination of behavioral assessments, and electrophysiological, biochemical, and immunohiotological analyses in the hippocampal CA1 region. A targeted pharmacological screen was conducted to evaluate the therapeutic potential of LEV. Vps35 deletion did not disrupt the gross brain development but led to progressive cognitive decline beginning at three months of age. Electrophysiological analyses revealed earlier-onset hippocampal CA1 hyperexcitability, marked by depolarized resting membrane potentials and reduced Kir2.1 expression. However, restoring Kir2.1 to suppress hyperexcitability failed to rescue cognitive deficits. Instead, cognitive impairment was associated with weakened GABAergic transmission and disruption of the excitatory/inhibitory balance in the Schaffer collateral-CA1 circuit. Notably, LEV treatment diminished these deficits in mutant mice. Intriguingly, LEV increased the levels of retromer component, VPS26A, and multiple pre- and postsynaptic GABAergic proteins, in addition to SV2A, all of which were reduced in Vps35-deficient CA1 neurons. These findings identify VPS35 in excitatory neurons as a critical factor for inhibitory synapse maintenance and network homeostasis. This study also highlights LEV as a potential therapeutic strategy for ADRDs through the preservation of GABAergic synapses.
中文摘要:阿尔茨海默病(AD)及相关痴呆(ADRDs)仍无法治愈,部分原因在于其致病机制复杂且认识不足。VPS35是逆转录体复合物的核心组分,其缺失与AD及ADRDs有关。已知Vps35缺陷可通过调控其货物蛋白如APP和BACE1而增加淀粉样蛋白生成,但VPS35功能障碍导致认知损害的精确机制仍不清楚。神经元VPS35调控多种突触膜蛋白的运输和功能,如突触后谷氨酸能受体、GABA能受体和突触前囊泡蛋白SV2A;左乙拉西坦(LEV)是一种改善认知的抗癫痫药,可与SV2A相互作用,但LEV如何增强认知仍有争议。鉴于VPS35在锥体兴奋性神经元中表达丰富,我们构建了条件性敲除小鼠模型,在出生后谷氨酸能兴奋性神经元中删除Vps35(Vps35CaMKIIα),并结合行为学评估以及海马CA1区的电生理、生化和免疫组织化学分析对其表型进行表征。还进行了靶向药理学筛选以评估LEV的治疗潜力。Vps35缺失未破坏大脑总体发育,但导致从3月龄开始出现进行性认知下降。电生理分析显示更早出现海马CA1过度兴奋,表现为静息膜电位去极化和Kir2.1表达降低。然而,恢复Kir2.1以抑制过度兴奋未能挽救认知缺陷。认知损害反而与GABA能传递减弱以及Schaffer侧支-CA1环路兴奋/抑制平衡破坏相关。LEV治疗减轻了突变小鼠的这些缺陷。有趣的是,LEV不仅增加SV2A水平,还提高了逆转录体组分VPS26A以及多种突触前和突触后GABA能蛋白的水平,而这些在Vps35缺陷的CA1神经元中均降低。这些发现确定兴奋性神经元中的VPS35是抑制性突触维持和网络稳态的关键因素。该研究还提示LEV可通过保护GABA能突触成为ADRD的潜在治疗策略。
Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial adaptation during Alzheimer's disease (AD), yet the development of small-molecule modulators associated with TREM2 signaling remains limited. Here, through a consensus pharmacophore-guided virtual screening strategy, MD2-IN-1 was identified as a candidate small molecule associated with TREM2 signaling. Biolayer interferometry and cellular thermal shift assays supported cellular target engagement related to TREM2 (KD = 13.85 μM). In Aβ-stimulated BV2 microglia, MD2-IN-1 increased SYK phosphorylation, promoted Aβ uptake, and shifted microglial responses toward a less proinflammatory phenotype. These effects were markedly attenuated following Trem2 knockdown, indicating the involvement of the TREM2-SYK signaling pathway. Mechanistically, MD2-IN-1 restored lysosomal acidification and increased the expression of the V-ATPase subunits ATP6v0c and ATP6v0a1, accompanied by increased intracellular Aβ degradation. In 5×FAD mice, chronic MD2-IN-1 administration improved cognitive performance without detectable behavioral abnormalities compared with WT animals. Multimodal PET imaging demonstrated reduced amyloid deposition and attenuated neuroinflammatory signals, which were further supported by histological analyses showing decreased plaque burden, reduced inflammatory microglial responses, and preserved neuronal integrity. In addition, MD2-IN-1 reduced P62 accumulation and restored ATP6v0c expression in vivo, whereas these effects were partially attenuated by pharmacological inhibition of TREM2. Collectively, these findings identify MD2-IN-1 as a small-molecule modulator associated with TREM2 signaling that restores microglial lysosomal degradative function and promotes Aβ clearance in AD models, providing pharmacological support for targeting adaptive microglial responses in AD.
中文摘要:髓样细胞触发受体2(TREM2)是阿尔茨海默病(AD)过程中小胶质细胞适应的核心调控因子,但与该受体信号相关的小分子调节剂开发仍有限。本研究通过共识药效团引导的虚拟筛选策略,鉴定出MD2-IN-1为与TREM2信号相关的候选小分子。生物层干涉技术和细胞热位移实验支持其与TREM2相关的细胞靶点结合(KD = 13.85 μM)。在Aβ刺激的BV2小胶质细胞中,MD2-IN-1增加SYK磷酸化,促进Aβ摄取,并使小胶质细胞反应向较低促炎表型转变。Trem2敲低后这些效应明显减弱,提示TREM2-SYK信号通路参与其中。机制上,MD2-IN-1恢复溶酶体酸化,增加V-ATPase亚基ATP6v0c和ATP6v0a1的表达,并伴随细胞内Aβ降解增加。在5×FAD小鼠中,长期给予MD2-IN-1改善认知表现,且与野生型动物相比未检测到行为异常。多模态PET成像显示淀粉样沉积减少和神经炎症信号减弱,组织学分析进一步支持这一点,表现为斑块负荷降低、炎性小胶质细胞反应减少和神经元完整性得以保持。此外,MD2-IN-1在体内减少P62蓄积并恢复ATP6v0c表达,而药理学抑制TREM2可部分减弱这些效应。总体而言,这些发现将MD2-IN-1鉴定为与TREM2信号相关的小分子调节剂,可恢复小胶质细胞溶酶体降解功能并促进AD模型中的Aβ清除,为靶向AD中小胶质细胞适应性反应提供药理学支持。
The pathogenic cascade of oxidative stress, neuroinflammation, and pyroptosis serves as a core driving factor in the pathogenesis and progression of Alzheimer's disease (AD). Although ginsenoside Rg1 exhibits pleiotropic neuroprotective activities, its poor blood-brain barrier (BBB) permeability severely hinders its clinical translation. To overcome this limitation, a brain-targeted delivery system was constructed using a covalent conjugation strategy, linking purified Rg1 with rhodamine B-modified polyethylene glycol (PEG) of varying chain lengths (Rg1s-PEG). After screening, the derivative Rg1s-PEG-600 was identified as achieving an optimal balance between hydrophilic stealth properties and steric hindrance, demonstrating enhanced brain accumulation and favorable biosafety profiles. In both in vitro and in vivo models of lipopolysaccharide-induced acute neuroinflammation, Rg1s-PEG-600 attenuated reactive oxygen species (ROS) accumulation, inhibited canonical neuronal pyroptosis mediated by the NLRP1/3 inflammasomes, and significantly ameliorated behavioral deficits and synaptic loss. Furthermore, in chronic 5xFAD transgenic mice, systemic administration of Rg1s-PEG-600 for 12 weeks markedly reversed spatial memory decline, anxiety-like behavior, and synaptic protein depletion. Mechanistic studies further revealed that this targeted nanotherapeutic not only suppressed the ROS-NLRP1 signaling axis and subsequent neuronal pyroptosis in the AD brain but also comprehensively inhibited amyloidogenesis and Tau hyperphosphorylation. This work provides a promising, multitarget nanotherapeutic strategy to overcome BBB limitations and disrupt the complex pathological networks underlying neurodegenerative diseases.
中文摘要:氧化应激、神经炎症与细胞焦亡构成的致病级联是阿尔茨海默病(AD)发生和进展的核心驱动因素。人参皂苷Rg1具有多效神经保护活性,但血脑屏障(BBB)透过性差严重阻碍其临床转化。为克服这一限制,采用共价偶联策略构建脑靶向递送系统,将纯化Rg1与不同链长的罗丹明B修饰聚乙二醇(PEG)连接(Rg1s-PEG)。筛选后,衍生物Rg1s-PEG-600在亲水隐身性与空间位阻之间取得较佳平衡,表现出增强的脑内蓄积和良好的生物安全性。在脂多糖诱导的急性神经炎症体外和体内模型中,Rg1s-PEG-600减少活性氧(ROS)蓄积,抑制NLRP1/3炎症小体介导的典型神经元焦亡,并明显改善行为缺陷和突触丢失。在慢性5xFAD转基因小鼠中,全身给予Rg1s-PEG-600 12周,显著逆转空间记忆下降、焦虑样行为和突触蛋白耗竭。机制研究进一步显示,该靶向纳米治疗不仅抑制AD脑内ROS-NLRP1信号轴及随后的神经元焦亡,还全面抑制淀粉样蛋白生成和Tau过度磷酸化。这项工作提供了一种有前景的多靶点纳米治疗策略,用以克服BBB限制并干预神经退行性疾病背后的复杂病理网络。
Alzheimer's disease (AD) remains a major cause of dementia, yet effective disease-modifying therapies are still limited. Although amyloid-β (Aβ) and tau pathology remain core features of AD pathogenesis, they do not fully explain how these pathological alterations drive progressive cellular dysfunction. Increasing evidence suggests that mitochondria are involved at this critical interface. In AD, mitochondrial abnormalities impair energy production, compromise organelle quality control, disrupt calcium (Ca2+) homeostasis, and alter communication with the endoplasmic reticulum and glial cells. As these defects accumulate, neurons and glia become less able to maintain metabolic stability, redox balance, and synaptic function. Mitochondrial dysfunction is therefore relevant to AD not as a single isolated lesion, but as a convergent process through which metabolic failure, oxidative stress, mitochondrial DNA damage, inflammatory signaling, and defective cellular maintenance reinforce one another. This perspective also helps explain why disease progression is difficult to reverse once mitochondrial homeostasis has been broadly compromised. At the same time, this framework also points to therapeutic opportunities, as the mechanisms driving the development and progression of mitochondrial dysfunction may be amenable to intervention. However, many mitochondria-centered strategies remain preclinical or have yielded inconsistent clinical benefit. Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.
中文摘要:阿尔茨海默病(AD)仍是痴呆的主要原因,但有效的疾病修饰治疗仍然有限。Aβ和tau病理仍是AD发病机制的核心特征,却不足以完整解释这些病理改变如何驱动进行性细胞功能障碍。越来越多证据提示线粒体处在这一关键界面。AD中线粒体异常损害能量产生,破坏细胞器质量控制,扰乱钙(Ca2+)稳态,并改变其与内质网及胶质细胞的通讯。这些缺陷累积后,神经元和胶质细胞维持代谢稳定、氧化还原平衡和突触功能的能力下降。因此,线粒体功能障碍与AD的相关性不在于单一孤立损伤,而在于它是一个汇聚过程,代谢失败、氧化应激、线粒体DNA损伤、炎症信号和细胞维护缺陷在其中相互强化。这一视角也有助于解释为何线粒体稳态广泛受损后疾病进展难以逆转。同一框架也指向治疗机会,因为驱动线粒体功能障碍发生和进展的机制可能适合干预。许多以线粒体为中心的策略仍处于临床前阶段,或临床获益不一致。现有证据支持线粒体功能障碍既是理解AD进展的有用机制基础,也是有生物学意义但具挑战性的治疗靶点。
Targeting microglia with adeno-associated viruses (AAVs) remains challenging because of inefficient transduction, off-target expression, and inconsistent payload performance. Here, we develop an integrated, Cre-independent AAV platform that combines a compact 446-bp microglia-specific regulatory element (MSRE), a high-yield AAV2/9.m capsid, microRNA-mediated neuronal de-targeting, and a microglia-tailored codon-optimization strategy. Following direct intracranial delivery, the optimized vector achieves robust, long-lasting transgene expression with greater than 90% microglial specificity across multiple mouse brain regions, including in an Alzheimer's disease model. With doxorubicin-assisted delivery, the platform also enables efficient and selective microglial targeting in rats, rhesus macaques, and human ex vivo brain slices. Codon optimization supports the expression of otherwise challenging functional payloads, enabling calcium imaging, chemogenetic manipulation, and CRISPR-Cas9-mediated genome editing. This cross-species toolkit provides a versatile resource for investigating microglial biology and developing microglia-directed therapeutic strategies.
中文摘要:用腺相关病毒(AAV)靶向小胶质细胞仍受转导效率低、脱靶表达和载荷表现不稳定等问题限制。研究构建了一个不依赖Cre的整合型AAV平台,组合446 bp的小胶质细胞特异性调控元件(MSRE)、高产量AAV2/9.m衣壳、微小RNA介导的神经元去靶向以及针对小胶质细胞定制的密码子优化策略。经颅内直接递送后,优化载体在多个小鼠脑区实现稳定、持久的转基因表达,小胶质细胞特异性超过90%,并在阿尔茨海默病模型中同样成立。借助多柔比星辅助递送,该平台还能在大鼠、恒河猴和人离体脑切片中实现高效、选择性小胶质细胞靶向。密码子优化支持原本较难表达的功能性载荷,使钙成像、化学遗传学操控和CRISPR-Cas9介导的基因组编辑得以开展。该跨物种工具集为研究小胶质细胞生物学和开发靶向小胶质细胞的治疗策略提供了通用资源。
Although Alzheimer's disease (AD) has a polygenic architecture, with numerous associated single-nucleotide polymorphisms (SNPs) identified, the contribution of structural variants (SVs) is unclear. In this study, using long-read (n = 11) and short-read (n = 3,190) sequencing data from the Chinese population, we show that common SVs contribute to AD heritability beyond common SNPs. We identify an expanded CCG repeat in the FAM193B promoter that shows a genome-wide significant association with increased AD risk (odds ratio = 2.20 per 10-repeat increase, P = 5.5 × 10-13). The expanded FAM193B-CCG repeat increases FAM193B expression and mediates the pleiotropic association between brain FAM193B expression and AD risk. Analyses of postmortem human brains and cultured neuronal cells show that elevated neuronal FAM193B expression is associated with DNA damage and cell death-related pathways. These findings establish the common FAM193B-CCG repeat as an AD risk genetic factor and highlight the contribution of common SVs to AD heritability.
中文摘要:阿尔茨海默病具有多基因架构,已鉴定出大量相关单核苷酸多态性,但结构变异的贡献尚不清楚。本研究利用中国人群的长读长(n=11)与短读长(n=3190)测序数据,显示常见结构变异对AD遗传力的贡献超出常见SNP之外。我们在FAM193B启动子区鉴定出一个扩增的CCG重复,其与AD风险升高在全基因组水平显著相关(每增加10个重复,比值比为2.20,P=5.5×10-13)。该扩增的FAM193B-CCG重复可提高FAM193B表达,并介导脑内FAM193B表达与AD风险之间的多效关联。对死后人脑与培养神经元细胞的分析显示,神经元FAM193B表达升高与DNA损伤及细胞死亡相关通路有关。这些结果确立常见FAM193B-CCG重复为AD风险的遗传因素,并提示常见结构变异对AD遗传力的贡献。
Alzheimer's disease (AD) is the most common cause of dementia and remains without a cure; recently introduced disease-modifying therapies provide only modest slowing in selected patients. Physical exercise is associated with better cognitive and functional outcomes, but the molecular mechanisms underlying these benefits remain incompletely understood. DNA methylation is a potential interface linking environmental stimuli to gene regulation and neural function. This narrative review examines evidence connecting exercise, DNA methylation, and AD, with emphasis on AD-related loci and on the possible intergenerational implications of parental exercise. We examine methylation findings involving amyloid precursor protein (APP) and presenilin-1 (PSEN1), which are relevant to amyloid-β production; microtubule-associated protein tau (MAPT), which encodes tau; and apolipoprotein E (APOE), which influences lipid transport and amyloid-β clearance. These findings suggest potential epigenetic contributions to AD-related biology, although their direction and functional significance vary across studies. We also discuss exercise-responsive pathways involved in energy sensing, autophagy, and redox signaling. We also evaluate whether exercise-associated epigenetic remodeling could influence amyloid-β accumulation, Tau homeostasis, and neuronal function. Evidence that exercise modifies DNA methylation is growing, whereas studies that integrate exercise interventions, genome-wide methylation, and AD-related outcomes remain scarce. Evidence for an inherited reduction in AD susceptibility is even more limited and currently supports a hypothesis rather than an established mechanism. Future studies integrating behavioral, neuropathological, cell-type-resolved epigenomic, and other multi-omic outcomes are needed to determine whether exercise-induced DNA methylation changes mediate neuroprotection in AD or primarily reflect broader physiological adaptation.
中文摘要:阿尔茨海默病(AD)是最常见的痴呆病因,目前仍无治愈手段;新近应用的疾病修饰治疗仅在部分患者中带来轻度延缓。体育锻炼与更好的认知和功能结局相关,但其背后的分子机制仍未充分阐明。DNA甲基化是连接环境刺激与基因调控及神经功能的潜在界面。这篇叙述性综述考察运动、DNA甲基化与AD之间关联的证据,重点讨论AD相关位点以及父母运动可能具有的跨代影响。我们审视涉及淀粉样前体蛋白(APP)和早老素1(PSEN1)的甲基化发现,这些基因与β淀粉样蛋白生成相关;涉及微管相关蛋白tau(MAPT)的发现,该基因编码tau;以及涉及载脂蛋白E(APOE)的发现,该基因影响脂质转运和β淀粉样蛋白清除。这些发现提示表观遗传因素可能参与AD相关生物学过程,但其方向和功能意义在不同研究中并不一致。我们还讨论参与能量感知、自噬和氧化还原信号的运动响应通路。我们评估运动相关表观遗传重塑是否可能影响β淀粉样蛋白蓄积、Tau稳态和神经元功能。运动改变DNA甲基化的证据正在增加,而将运动干预、全基因组甲基化与AD相关结局整合起来的研究仍然很少。关于AD易感性可经遗传降低的证据更为有限,目前支持的是一种假说而非已确立的机制。未来需要整合行为学、神经病理学、细胞类型分辨的表观基因组学及其他多组学结局的研究,以判断运动诱导的DNA甲基化变化是否介导AD中的神经保护,还是主要反映更广泛的生理适应。
Alzheimer's disease (AD) disproportionately affects women, yet mechanisms underlying this sex difference remain unclear. Histone variants are overrepresented components of aging neuronal chromatin, but their contribution to AD is unknown. Here, we identify the histone variant H2A.Z as a sex-specific regulator of AD in the postmortem human hippocampus and in 5xFAD mice. H2A.Z occupancy decreased in female but increased in male AD patients. In females, reduced H2A.Z occupancy at the transcription start site (TSS) occurred despite increased total H2A.Z, indicating that H2A.Z is redistributed to sites of lower H2A.Z occupancy. Similar sex-dependent alterations were observed in 5xFAD mice over disease progression. Whereas H2A.Z.1 depletion improved memory and AD pathology in females at early and late disease stages, it impaired memory in male mice at early stages and improved memory in late stages. Together, these data identify H2A.Z as a regulator of sex- and stage-dependent AD outcomes, with implications for the sex-specific therapeutic targeting of chromatin factors.
中文摘要:阿尔茨海默病(AD)对女性的影响不成比例,但这种性别差异的机制仍不清楚。组蛋白变体是衰老神经元染色质中占比偏高的组分,但它们对AD的贡献未知。我们在死后人海马和5xFAD小鼠中鉴定组蛋白变体H2A.Z是AD的性别特异性调控因子。H2A.Z占据在女性AD患者中减少,在男性AD患者中增加。在女性中,转录起始位点(TSS)处H2A.Z占据减少,尽管总H2A.Z增加,提示H2A.Z被重新分布至H2A.Z占据较低的位点。在5xFAD小鼠疾病进展过程中观察到相似的性别依赖性改变。耗竭H2A.Z.1在疾病早期和晚期改善雌性小鼠记忆和AD病理,而在雄性小鼠早期阶段损害记忆、晚期阶段改善记忆。这些数据表明H2A.Z调控AD结局的性别和阶段依赖性,对染色质因子的性别特异性治疗靶向具有意义。
3帕金森病与运动障碍 (6篇)
临床研究 (2篇)
Progressive supranuclear palsy (PSP) is an adult-onset neurodegenerative disease with a heterogeneous spectrum of clinical and pathological features. The epidemiology of PSP-as defined by the gold standard of autopsy diagnosis-remains unresolved, but prevalence estimates are typically ~1:10,000. Here, we analyzed the National Alzheimer's Coordinating Center (NACC) Neuropathology Data Set, aggregated from 38 U.S. Alzheimer's Disease Research Centers (ADRCs). We compared clinical and neuropathologic features of autopsied participants, stratifying on cognitive status at recruitment into the cohort. The sample comprised 6845 individuals who were followed longitudinally for 4.0 (± 2.9 stdev) approximately yearly visits, n = 297 with eventual autopsy-verified PSP. Participants were not necessarily diagnosed or followed in movement disorder clinics. Among those with dementia or PSP at recruitment (n = 4310), 3.3% had corticobasal degeneration (CBD), 3.0% Pick's disease, and 4.5% PSP pathology. Among those recruited while cognitively normal (n = 1451), 0.7% had CBD, and 0.1% Pick's disease, while 3.2% had PSP pathology. This frequency of incident PSP pathology was higher than expected based on prior epidemiology studies. In comparing between incident (recruited normal) and prevalent (recruited with dementia or clinical PSP) cases with PSP pathology, those with incident PSP died older: 89.5 years vs 76.3 years on average. Furthermore, incident PSP pathology cases were less likely to manifest stereotypical PSP clinical features, but more likely to have parkinsonism. In a convenience sample of individuals with PSP pathology from the University of Kentucky ADRC (n = 23), digital pathology analyses using HALO software and AI-based analytic modules revealed that PSP tau pathology was more severe overall in prevalent PSP. Within the putamen, incident cases had a higher proportion of tufted astrocytes and lower proportion of NFTs. In conclusion, in this large multicenter sample, PSP pathology was more common than other FTLD-Tau subtypes, and incident PSP often differed clinically from "classic" PSP.
中文摘要:进行性核上性麻痹(PSP)是一种成年起病的神经退行性疾病,其临床与病理特征谱系高度异质。以尸检诊断为金标准所定义的PSP流行病学仍未阐明,患病率估计通常约为万分之一。我们分析了美国国家阿尔茨海默病协调中心(NACC)神经病理数据集,该数据集汇集自38家美国阿尔茨海默病研究中心(ADRC)。按入组时的认知状态分层,比较接受尸检参与者的临床与神经病理特征。样本共6845人,纵向随访4.0(±2.9标准差)年,约每年一次访视,其中297例最终经尸检证实为PSP。参与者未必在运动障碍门诊被诊断或随访。在入组时已有痴呆或PSP的患者(n=4310)中,3.3%存在皮质基底节变性(CBD)、3.0%为皮克病、4.5%有PSP病理。在入组时认知正常者(n=1451)中,0.7%有CBD、0.1%有皮克病,3.2%有PSP病理。这一新发PSP病理的频率高于既往流行病学研究预期。比较有PSP病理的新发病例(入组时认知正常)与现患病例(入组时已有痴呆或临床PSP),新发病例死亡年龄更大:平均89.5岁对76.3岁。新发PSP病理病例较少表现出典型PSP临床特征,但更常出现帕金森综合征。在肯塔基大学ADRC一个有PSP病理的便利样本(n=23)中,使用HALO软件与基于人工智能的分析模块进行数字病理分析,显示现患PSP的tau病理总体更重。在壳核内,新发病例簇状星形胶质细胞比例更高,神经原纤维缠结比例更低。在这一大型多中心样本中,PSP病理比其他FTLD-Tau亚型更常见,新发PSP在临床上常与「经典」PSP不同。
Current non-invasive assessments for Parkinson's disease (PD) are predominantly single-modality, leaving an unmet need for an integrated platform combining biomolecular and biomechanical detection. Here, an integrated dual-mode sensing platform based on a flexible non-woven fabric (NWFs) device for PD is provided. Silver nano-contacts are electrolessly deposited onto cotton fibers to form a biomimetic spider-leg-like microarchitecture, which concurrently supports localized surface plasmon resonance (LSPR) for surface-enhanced Raman scattering (SERS) and strain-responsive piezoresistive behavior. The NWFs@Au@Ag substrate exhibits good cytocompatibility with 100% cell viability. Using the NWFs@Au@Ag SERS substrate for standard α-synuclein molecule testing, the 1670-1680 cm-1 band verifies the formation of β-sheet-rich amyloid aggregates. In saliva from PD and MSA patients, SERS detects spectral signatures associated with α-synuclein, most notably an altered amide I band at 1677 cm-1 and the difference in β-sheet is one of the important contributors to the spectral differences. Simultaneously, the piezoresistive mode quantitatively monitors orbicularis oculi strain during blink and eye-scanning movements. The strain signals show strong concordance with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (Part III), and capture disease progression and acute levodopa response with temporal resolution superior to conventional electromyography (EMG). In 30 PD patients, artificial intelligence-assisted analysis of horizontal eye-scanning strain waveforms achieves 90.9% classification accuracy. By combining biomolecular fingerprinting and biomechanical function assessment, this dual-mode platform could overcome the single-modality limitation of existing PD non-invasive evaluation methods and offer an explorable path for point-of-care screening and longitudinal monitoring of disease progression.
中文摘要:目前帕金森病(PD)的无创评估多为单一模态,仍缺乏将生物分子检测与生物力学检测结合的一体化平台。为此,研究构建了一种基于柔性无纺布(NWFs)器件的PD双模态集成传感平台。通过化学镀在棉纤维上沉积银纳米接触,形成仿蜘蛛腿状微结构,该结构同时支持用于表面增强拉曼散射(SERS)的局域表面等离激元共振(LSPR)和应变响应压阻行为。NWFs@Au@Ag基底具有良好细胞相容性,细胞存活率为100%。采用NWFs@Au@Ag SERS基底检测标准α-突触核蛋白分子时,1670–1680 cm-1谱带证实形成富含β折叠的淀粉样聚集体。在PD和MSA患者唾液中,SERS检测到与α-突触核蛋白相关的光谱特征,最突出的是1677 cm-1处酰胺I带改变,β折叠差异是光谱差异的重要贡献因素之一。同时,压阻模式定量监测眨眼和扫视运动时眼轮匝肌应变。应变信号与运动障碍学会统一帕金森病评定量表(Part III)高度一致,并能捕捉疾病进展和急性左旋多巴反应,时间分辨率优于常规肌电图(EMG)。在30例PD患者中,人工智能辅助分析水平扫视应变波形实现90.9%分类准确率。通过结合生物分子指纹和生物力学功能评估,该双模态平台可克服现有PD无创评估方法的单模态局限,为即时筛查和疾病进展纵向监测提供可探索路径。
基础研究 (4篇)
α-Synuclein (α-Syn) accumulation is a defining feature of Parkinson's disease (PD). Zhang et al. identify cholesterol 25-hydroxylase (CH25H) as an astrocytic inhibitor of p62-dependent α-Syn degradation. Disrupting the CH25H-p62 interaction facilitates α-Syn clearance via autophagy and improves PD-like phenotypes, suggesting a previously unrecognized nonenzymatic function for CH25H with therapeutic potential.
中文摘要:α-Syn累积是帕金森病的核心特征。Zhang等发现胆固醇25-羟化酶(CH25H)是星形胶质细胞中p62依赖性α-Syn降解的抑制因子。破坏CH25H与p62的相互作用可通过自噬促进α-Syn清除,并改善帕金森病样表型,提示CH25H具有此前未被认识的非酶功能,并具治疗潜力。
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, a cornerstone of innate immunity, has emerged as a critical driver of sterile neuroinflammation in the aging brain. Age-related decline in mitochondrial quality control, coupled with nuclear and lysosomal erosion, fosters the aberrant accumulation of cytosolic self-DNA, establishing a permissive environment for chronic cGAS-STING activation. This review synthesizes recent breakthroughs elucidating how major neurodegenerative diseases-Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease-converge on this pathway through distinct, disease-specific triggers, ranging from PINK1/Parkin deficiency-driven mitochondrial DNA leakage to TDP-43 proteinopathy-associated retrotransposon de-repression. Critically, we evaluate the translational landscape, highlighting the profound challenge posed by species-specific pharmacology, as exemplified by the failure of the covalent inhibitor H-151 to engage human STING. We argue that the future of therapeutic intervention lies not in wholesale pathway ablation, but in nuanced, context-dependent fine-tuning that disentangles its detrimental chronic effects from its indispensable homeostatic functions. This review positions the cGAS-STING axis as a promising yet delicate frontier for combating age-related neurodegeneration.
中文摘要:环鸟苷酸-腺苷酸合成酶(cGAS)-干扰素基因刺激蛋白(STING)通路是天然免疫的基石,已成为衰老脑中无菌性神经炎症的关键驱动因素。线粒体质量控制随年龄下降,加上核与溶酶体受损,促进胞质自身DNA异常积累,为cGAS-STING慢性激活创造允许环境。近期突破阐明,阿尔茨海默病、帕金森病、肌萎缩侧索硬化、亨廷顿病等主要神经退行性疾病通过不同疾病特异性触发因素汇聚到该通路,从PINK1/Parkin缺陷驱动的线粒体DNA泄漏到TDP-43蛋白病相关的逆转录转座子去抑制。转化前景评估显示,种属特异性药理学带来严峻挑战,共价抑制剂H-151无法结合人STING即为示例。治疗干预的未来不在于全面消除该通路,而在于精细、依赖情境的微调,将其有害的慢性效应与不可或缺的稳态功能区分开来。cGAS-STING轴因此被视为对抗年龄相关神经退行性疾病一个有前景但需谨慎对待的前沿。
Mutations in coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2), including the Parkinson's disease (PD)-linked CHCHD2T61I mutation, are associated with Lewy body disorders (LBDs) by unknown mechanisms. Here, we demonstrate that CHCHD2T61I exacerbates age-related brain pathologies, including axonal degeneration and cognitive deficits, by disrupting the mitochondria-lysosome axis. Specifically, CHCHD2T61I binds and reduces cathepsin B (CTSB) and cathepsin L (CTSL) levels, inducing lysosomal membrane permeability and impairing α-synuclein fibril clearance. We also demonstrate that human CHCHD2 declines in the brain with age, while expression of wild-type CHCHD2 safeguards against age-related neuroinflammation, dopaminergic neuron loss, insoluble protein aggregation, and structural deterioration of mitochondria and lysosomes. These findings, supported by observed reductions in CTSB and CHCHD2 in human LBD brains, establish CHCHD2 as a key regulator of neuronal resilience to aging and proteostatic collapse via the mitochondria-lysosome axis. Preventing age-associated CHCHD2 decline offers a therapeutic strategy to preserve brain health throughout aging.
中文摘要:卷曲螺旋-螺旋-卷曲螺旋-螺旋结构域蛋白2(CHCHD2)的突变,包括与帕金森病(PD)相关的CHCHD2T61I突变,与路易体病(LBDs)相关,但机制尚不清楚。本研究报告CHCHD2T61I通过破坏线粒体-溶酶体轴,加重与年龄相关的脑部病理改变,包括轴索变性和认知功能缺损。具体而言,CHCHD2T61I结合并降低组织蛋白酶B(CTSB)和组织蛋白酶L(CTSL)的水平,诱导溶酶体膜通透性升高,削弱α-突触核蛋白纤维的清除。人脑中的CHCHD2随年龄增长而下降,而野生型CHCHD2的表达可防止与年龄相关的神经炎症、多巴胺能神经元丢失、不溶性蛋白聚集以及线粒体和溶酶体的结构退变。这些结果,连同在人类LBD脑组织中观察到的CTSB和CHCHD2降低,确立CHCHD2是经线粒体-溶酶体轴调控神经元对衰老与蛋白稳态崩溃耐受性的关键因子。阻止随年龄发生的CHCHD2下降,为在整个衰老过程中维护脑健康提供了治疗策略。
Iron-driven reactive oxygen species (ROS) amplification forms a self-sustaining pathological cycle in Parkinson's disease (PD), yet remains difficult to therapeutically interrupt due to the lack of strategies that coordinate metal homeostasis and redox regulation. Here, we report an electronic-structure-engineered nanoregulatory strategy that regulates the iron-ROS cycle rather than passively scavenging ROS. Nitrogen-doped, herbal-derived carbon dots (CD) were rationally constructed to establish a conjugated electronic framework, in which heteroatom-induced electron delocalization defined redox-active sites and governed the coupling between iron chelation and catalytic ROS regulation. This structure-electronic state-function relationship enabled programmable disruption of the iron-ROS feedback loop at its source. Functionally, the nanoregulators achieved low-density lipoprotein receptor-related protein 1 (LRP1)-mediated brain delivery, exhibited efficient central nervous system exposure, and underwent brain clearance via the cerebrospinal fluid pathway. At the cellular level, they restored mitochondrial function, suppressed ferroptosis-associated lipid peroxidation, and reprogramed stress-related pathways toward neuronal survival. Transcriptomic analysis further revealed coordinated regulation of redox, metabolic, and inflammatory networks. In Parkinsonian mice, this strategy reduced iron deposition, preserved dopaminergic neurons, and improved motor function. Integration with levodopa further enabled sustained, disease-modifying neuroprotection.
中文摘要:铁驱动的活性氧(ROS)放大在帕金森病(PD)中形成自我维持的病理循环,但缺乏协调金属稳态与氧化还原调控的策略,治疗上难以打断。我们报道一种电子结构工程化的纳米调控策略,调控铁-ROS循环而非被动清除ROS。理性构建氮掺杂的草药来源碳点(CD),建立共轭电子框架,其中杂原子诱导的电子离域界定氧化还原活性位点,并支配铁螯合与催化性ROS调控之间的耦合。这种结构-电子态-功能关系使铁-ROS反馈环路可在源头被可编程地破坏。功能上,纳米调控器经低密度脂蛋白受体相关蛋白1(LRP1)介导实现脑内递送,具有有效的中枢神经系统暴露,并经脑脊液途径清除。细胞层面,其恢复线粒体功能,抑制铁死亡相关脂质过氧化,并将应激相关通路重编程向神经元存活。转录组分析进一步显示对氧化还原、代谢和炎症网络的协同调控。在帕金森病小鼠中,该策略减少铁沉积,保护多巴胺能神经元,改善运动功能。与左旋多巴联合进一步实现持续的疾病修饰性神经保护。
4癫痫 (3篇)
临床研究 (2篇)
Canopy FGF signalling regulator 3 (CNPY3) is an endoplasmic reticulum (ER)-resident chaperone essential for toll-like receptor (TLR) folding, trafficking and inflammasome activation. In rare paediatric cases, biallelic CNPY3 variants have been associated with developmental and epileptic encephalopathy (DEE), but available data remain sparse. 50 individuals from 38 unrelated families with biallelic CNPY3 variants and DEE were evaluated for exome and genome findings, standardised clinical phenotype descriptions, EEG results, and neuroimaging data. A selection of variants underwent functional analysis focussing on protein stability and localisation, TLR2 function, NLPR3 inflammasome activation, and structural conformation. Disease onset occurred in early infancy (median age at onset 68 days), with a clinical phenotype comprising global developmental delay (100%) and intractable epilepsy (86%), accompanied by microcephaly (70%), spasticity (77%), growth faltering (63%), stridor (48%), and early mortality (38%). Epileptic spasms and tonic seizures (46% each) were the most frequent seizure types, and EEG findings included suppression-burst (37%) and hypsarrhythmia (28%). Phenotypic severity varied substantially, with most patients being severely affected (median score 16, range 2-20). Most variants occurred in the homozygous state (95%), including 13 missense changes and 7 truncating alleles. Variants were classified as of uncertain significance (71%), followed by likely pathogenic (23%) and pathogenic (6%) according to ACMG/AMP criteria. Genotype-phenotype correlation showed that individuals with truncating variants were, on average, more severely affected than those with non-truncating variants (median score 18 vs 14.5). Protein modelling predicted conformational effects for most missense variants. In cells, frameshift alleles abolished CNPY3 protein expression, whereas nonsense alleles markedly reduced protein levels. ER localisation of CNPY3 remained preserved across tested genotypes; however, capacity to support TLR2 maturation and processing varied substantially. Remarkably, some missense variants permitted TLR2 surface expression but impaired downstream signalling and inflammasome activation, uncoupling trafficking from signal transduction. CNPY3-associated DEE is a severe early-onset disorder with genotype-dependent phenotypic severity, accompanied by allele-specific disruption of innate immune pathways. Our findings reveal separable effects on TLR trafficking, downstream signalling and inflammasome activation, identifying CNPY3 as a key regulator of multiple cellular pathways involved in inflammatory responses and neurodevelopment. Interdisciplinary Center of Clinical Research and Jena School of Molecular Medicine, Jena University Hospital; Friedrich Schiller University Jena; The Wellcome Trust; The Medical Research Council; The MSA Trust; The National Institute for Health Research University College London Hospitals Biomedical Research Centre; The Michael J Fox Foundation; Biotechnology and Biological Sciences Research Council; The Fidelity Trust; Rosetrees Trust; Ataxia UK; Brain Research UK; Sparks GOSH Charity; Alzheimer's Research UK; CureDRPLA; UK Dementia Research Institute; Parkinson's UK; South-Eastern Norway Regional Health Authority, Norway; France Genomic Medicine Plan 2025; Deutsche Forschungsgemeinschaft; European Commission; Federal Government of Germany; State of Thuringia; Pakistan Science Foundation; King Abdullah International Medical Research Center; Science and Technology Development Fund; King Salman Center for Disability Research.
中文摘要:Canopy FGF信号调节因子3(CNPY3)是一种驻留于内质网的分子伴侣,对Toll样受体(TLR)折叠、运输和炎症小体激活必不可少。罕见儿科病例中,双等位基因CNPY3变异与发育性和癫痫性脑病(DEE)相关,但现有数据仍有限。研究纳入来自38个无亲缘关系家系的50例携带双等位基因CNPY3变异并患DEE的个体,评估外显子组和基因组结果、标准化临床表型描述、脑电图结果及神经影像数据。选取部分变异进行功能分析,聚焦蛋白稳定性与定位、TLR2功能、NLRP3炎症小体激活及结构构象。疾病起病于婴儿早期(起病中位年龄68天),临床表型包括全面发育迟缓(100%)和难治性癫痫(86%),并伴小头畸形(70%)、痉挛状态(77%)、生长迟缓(63%)、喘鸣(48%)和早期死亡(38%)。癫痫性痉挛和强直发作最常见(各46%),脑电图可见爆发抑制(37%)和高度失律(28%)。表型严重程度差异明显,多数患者受累严重(中位评分16,范围2-20)。大多数变异为纯合状态(95%),包括13个错义变异和7个截短等位基因。按ACMG/AMP标准,变异分类为意义未明(71%)、可能致病(23%)和致病(6%)。基因型-表型相关分析显示,携带截短变异的个体平均比携带非截短变异的个体受累更重(中位评分18对14.5)。蛋白建模预测多数错义变异存在构象影响。细胞中,移码等位基因使CNPY3蛋白表达消失,无义等位基因明显降低蛋白水平。受试基因型中CNPY3的内质网定位均保留,但支持TLR2成熟和加工的能力差异很大。部分错义变异允许TLR2表面表达,却损害下游信号传导和炎症小体激活,使运输与信号转导解耦。CNPY3相关DEE是一种严重的早发型疾病,表型严重程度依赖基因型,并伴随先天免疫通路的等位基因特异性破坏。研究结果揭示了对TLR运输、下游信号传导和炎症小体激活的可分离影响,将CNPY3确定为参与炎症反应和神经发育的多个细胞通路的关键调节因子。资助来源包括耶拿大学医院临床研究跨学科中心与耶拿分子医学学院、Friedrich Schiller University Jena、The Wellcome Trust、The Medical Research Council、The MSA Trust、The National Institute for Health Research University College London Hospitals Biomedical Research Centre、The Michael J Fox Foundation、Biotechnology and Biological Sciences Research Council、The Fidelity Trust、Rosetrees Trust、Ataxia UK、Brain Research UK、Sparks GOSH Charity、Alzheimer's Research UK、CureDRPLA、UK Dementia Research Institute、Parkinson's UK、挪威东南地区卫生局、法国基因组医学计划2025、Deutsche Forschungsgemeinschaft、European Commission、德国联邦政府、图林根州、Pakistan Science Foundation、King Abdullah International Medical Research Center、Science and Technology Development Fund、King Salman Center for Disability Research。
One-third of the world's 70 million people with epilepsy have seizures uncontrolled by medication, and implantable devices are a promising treatment. These devices can detect impending seizures, missed medication and impaired cognition, but, like most medical devices, they cannot share this information with patients in real time. This is a missed opportunity for devices to learn from clinical events and teach patients how their behaviors affect their health. Here we present a device platform that converses with patients to help them manage their epilepsy. The inpatient prototype links scalp and intracranial electroencephalography (EEG) to a secure, large language model-based artificial intelligence (AI) that communicates bidirectionally through a smartphone app. The AI processes biomarkers of sleep, medication, cognition and seizure probability, notifies patients of clinical events and trends, records symptoms and responses, and uses their feedback to retrain its seizure detector, reducing false alarms. We validated this platform in 13 patients who are undergoing video-EEG monitoring for epilepsy (scalp, n = 11; intracranial, n = 2). In a pseudoprospective simulation, seizure detectors improved precision from patient feedback alone, without expert intervention. We propose this system as a scalable, safeguarded platform for medical devices that can rapidly adapt to patient and provider needs across epilepsy and other medical conditions.
中文摘要:全球7000万癫痫患者中有三分之一的人发作无法通过药物控制,植入式设备是一种有前景的治疗方法。这类设备可以检测即将发生的癫痫发作、漏服药物和认知功能受损,但与大多数医疗设备一样,它们无法实时与患者共享这些信息。设备因此失去了从临床事件中学习并让患者了解自身行为如何影响健康的机会。这里介绍一个与患者对话以帮助其管理癫痫的设备平台。住院原型将头皮和颅内脑电图与安全的、基于大语言模型的人工智能相连,通过智能手机应用进行双向通信。该人工智能处理睡眠、用药、认知和癫痫发作概率的生物标志物,向患者通知临床事件和趋势,记录症状和反应,并利用患者反馈重新训练其癫痫检测器,减少误报。研究在13名因癫痫接受视频脑电图监测的患者中验证了该平台(头皮11例;颅内2例)。在伪前瞻性模拟中,仅凭患者反馈、无需专家干预,癫痫检测器的精确度即得到提高。研究提出这一系统可作为可扩展、有安全保障的医疗设备平台,能够快速适应癫痫及其他疾病中患者和医疗服务提供者的需求。
基础研究 (1篇)
Diffuse gliomas are frequently associated with epilepsy, particularly in low-grade variants. Seizures are key events to be considered in glioma management, including during surgery. Optimizing resection of epileptic areas may affect not only postoperative epilepsy but also glioma prognosis in the context of interactions between glioma growth and neuronal activities. As for glioma tissue resection, surgery of epileptic networks requires a deeper understanding of their organization and reliable biomarkers. We investigated the spatiotemporal dynamics of the transition from interictal to ictal-like events (ILEs) using ex vivo human peritumoral tissue from glioma patients. Slices were recorded with multi-electrode arrays during the transition from the spontaneous interictal state to pharmacologically induced seizures considering the dynamics of slow versus fast oscillatory neuronal activities. Transition to seizure was characterized by the emergence of preictal discharges (PIDs), allowing subdivision of the preictal phase into build-up, steady-state, and trigger periods. PIDs progressively increased in amplitude, duration, and slope with significant changes during the trigger phase. Concurrently, high-frequency activity (180-550 Hz) and high-frequency oscillations (HFOs) increased across the transition period, particularly during the trigger phase. In addition to such preictal recruitment, the reinforcement of HFOs was accompanied by a spatial organization in additive microdomains, peaking at seizure onset and encompassing slow field potential dynamics. In the periglioma human cortex, seizures arise from progressively recruited neuronal assemblies sculpted together with HFOs, providing new insights into the microphysiological processes of glioma-related ictogenesis and requiring consideration of the preictal fast and focal neuronal activity.
中文摘要:弥漫性胶质瘤常与癫痫相关,低级别变异型尤为明显。癫痫发作是胶质瘤管理中需考虑的关键事件,包括手术期间。优化癫痫区域切除可能不仅影响术后癫痫,在胶质瘤生长与神经元活动相互作用的背景下,也可能影响胶质瘤预后。与胶质瘤组织切除类似,癫痫网络手术需要更深入理解其组织方式和可靠生物标志物。我们利用胶质瘤患者离体人瘤周组织,研究从发作间期向发作样事件(ILEs)转变的时空动态。考虑慢速与快速振荡神经元活动的动态变化,在从自发性发作间期状态向药物诱导癫痫转变过程中,用多电极阵列记录脑片。向癫痫发作的转变以发作前放电(PIDs)出现为特征,使发作前期可细分为累积期、稳定期和触发期。PIDs的波幅、持续时间和斜率逐步增加,并在触发期出现显著变化。与此同时,高频活动(180-550 Hz)和高频振荡(HFOs)在整个转变期增加,尤其在触发期。除这种发作前募集外,HFOs的增强伴随空间上叠加微域的组织,在癫痫发作起始时达到峰值,并涵盖慢场电位动态。在胶质瘤周围人皮质中,癫痫发作源于与HFOs共同塑造、逐步募集的神经元组装,为胶质瘤相关致癫痫发生的微生理过程提供新见解,并提示需要考虑发作前快速和局灶性神经元活动。
5神经肌肉病与周围神经 (3篇)
临床研究 (1篇)
While serum neurofilament light chain (sNfL) has shown promise as a biomarker for the development of peripheral neuropathy (PN) in hereditary transthyretin (TTR) amyloidosis (vATTR), its role in all-comers with ATTR cardiomyopathy (ATTR-CM) is less well-defined, and it is unknown how CM severity and TTR stabilizer therapy affect sNfL in ATTR-CM. Study participants included those with ATTR-CM not on gene-silencer therapy referred to Oregon Health & Science University. The association between sNfL and baseline patient characteristics, including age, sex, body mass index (BMI), presence of PN, ATTR subtype, N-terminal pro b-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR) and tafamidis treatment, were evaluated utilizing linear regression. 66 patients (age: 78.5 ± 6.9 years, 6.1% female, 16.7% with diabetes mellitus, 10.6% vATTR-CM, 43.9% with PN symptoms, 30.3% receiving tafamidis at baseline) were included. There was no difference in sNfL levels when stratified by ATTR subtype (p = 0.168), PN symptoms (p = 0.881), or tafamidis treatment measured categorically (p = 0.418). In 17 patients (17.6% vATTR-CM) with available paired pre-tafamidis and on-tafamidis samples, there was no difference in sNfL level. In our univariable and multivariable analysis, NT-proBNP and eGFR were associated with sNfL. In ATTR-CM, cardiomyopathy severity and renal dysfunction impact sNfL more than presence of PN or other clinical factors.
中文摘要:血清神经丝轻链(sNfL)在遗传性转甲状腺素蛋白(TTR)淀粉样变性(vATTR)中作为周围神经病变(PN)发生标志物已有前景,但在所有ATTR心肌病(ATTR-CM)患者中的作用尚不明确,且心肌病严重程度和TTR稳定剂治疗如何影响ATTR-CM的sNfL仍未知。研究参与者为转诊至俄勒冈健康与科学大学、未接受基因沉默治疗的ATTR-CM患者。采用线性回归评估sNfL与基线患者特征(包括年龄、性别、体重指数、PN存在、ATTR亚型、N末端B型利钠肽原、估算肾小球滤过率和氯苯唑酸治疗)之间的关联。共纳入66例患者(年龄78.5±6.9岁,女性6.1%,糖尿病16.7%,vATTR-CM 10.6%,有PN症状43.9%,基线接受氯苯唑酸30.3%)。按ATTR亚型(p=0.168)、PN症状(p=0.881)或氯苯唑酸治疗分类(p=0.418)分层时,sNfL水平无差异。在17例有配对氯苯唑酸治疗前和治疗中样本的患者(vATTR-CM 17.6%)中,sNfL水平无差异。单变量和多变量分析中,NT-proBNP和eGFR与sNfL相关。在ATTR-CM中,心肌病严重程度和肾功能不全对sNfL的影响大于PN存在或其他临床因素。
基础研究 (2篇)
Sensory neurons innervate the tumor microenvironment (TME) and are active contributors to tumor progression and immune evasion. Across multiple cancer types, higher intratumoral nerve density is associated with worse clinical outcomes, including increased lymph node metastasis, local recurrence, and reduced survival. This relationship is driven, at least in part, by local immunosuppression arising from neuropeptide and neurotransmitter paracrine signaling within the TME. Nociceptive sensory neurotransmission impacts tumor-infiltrating immune cells to promote T-cell exhaustion, mast cell degranulation, and stromal remodeling, collectively constructing a barrier to effective antitumor immunity. Beyond paracrine signaling, sensory neurons themselves express immune checkpoint proteins, including programmed cell death ligand-1, providing an additional mechanism by which the sensory nervous system participates in local immune regulation. Preclinical studies have established that targeting sensory neuron signaling, whether through denervation, neuropeptide antagonism, or axon guidance inhibition, can relieve TME immunosuppression and improve the efficacy of immune-based therapies. Several Food and Drug Administration (FDA)-approved agents developed for non-oncologic indications, including calcitonin gene-related peptide receptor antagonists approved for migraine, and the NK-1R antagonist Aprepitant, represent immediately available candidates for repurposing in combination immunotherapy strategies. The relationship between sensory neurons and immunotherapy is bidirectional; however, immunotherapies also act on sensory neurons, and this interaction likely contributes to the development and severity of immune-related adverse events through disruption of constitutive neuronal checkpoint signaling and neurogenic amplification of tissue inflammation. Sensory neurons in densely innervated barrier organs may serve as neuroimmune amplifiers that worsen the severity of colitis, pneumonitis, and dermatitis during checkpoint blockade. This review examines the evidence for how sensory neural signaling shapes immunotherapy efficacy, and how immunotherapies impinge on sensory neuron biology to promote adverse events. Throughout, we highlight translational opportunities where modulation of the sensory nervous system may improve therapeutic outcomes or reduce treatment toxicity.
中文摘要:感觉神经元支配肿瘤微环境(TME),并主动参与肿瘤进展和免疫逃逸。在多种癌种中,瘤内神经密度较高与更差的临床结局相关,包括淋巴结转移增加、局部复发和生存期缩短。这种关系至少部分源于TME内神经肽和神经递质旁分泌信号造成的局部免疫抑制。伤害性感觉神经传递作用于肿瘤浸润免疫细胞,促进T细胞耗竭、肥大细胞脱颗粒和基质重塑,共同构筑阻碍有效抗肿瘤免疫的屏障。除旁分泌信号外,感觉神经元自身表达免疫检查点蛋白,包括程序性死亡配体-1(PD-L1),这为感觉神经系统参与局部免疫调节提供了另一机制。临床前研究已证实,靶向感觉神经元信号,无论是通过去神经支配、神经肽拮抗还是轴突导向抑制,都能缓解TME免疫抑制并提高免疫治疗疗效。若干因非肿瘤适应症获批的FDA药物,包括获批用于偏头痛的降钙素基因相关肽受体拮抗剂和NK-1R拮抗剂阿瑞匹坦,是可直接用于联合免疫治疗策略重定位的候选药物。感觉神经元与免疫治疗之间呈双向关系;免疫治疗也作用于感觉神经元,这种相互作用可能通过破坏组成性神经元检查点信号和神经源性放大组织炎症,促成免疫相关不良事件的发生和严重程度。在神经支配密集的屏障器官中,感觉神经元可能作为神经免疫放大器,在检查点阻断期间加重结肠炎、肺炎和皮炎。该综述考察感觉神经信号如何塑造免疫治疗疗效,以及免疫治疗如何影响感觉神经元生物学并促进不良事件。全篇强调通过调节感觉神经系统改善治疗结局或降低治疗毒性的转化机会。
Systemic exposure to neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects both the central nervous system (CNS) and peripheral organs; however, the contribution of peripheral organ stress to neuroinflammation remains incompletely understood. Here, we propose a peripheral-to-central signaling mechanism in which renal stress-associated extracellular vesicles (EVs) are linked to microglial inflammasome activation. Using computational and biochemical approaches, cathepsin D (CTSD) was identified as a molecular target of the MPTP metabolite 1-methyl-4-phenylpyridinium (MPP +). MPP + accumulated in renal tissue and was associated with lysosomal stress and tubular injury, accompanied by increased release of circulating EVs enriched with renal injury markers. Pharmacological inhibition of pepstatin A-sensitive lysosomal protease activity attenuated renal injury and EV release. MPTP exposure was also associated with blood-brain barrier disruption, potentially permitting circulating EV-associated signaling to influence the CNS. Plasma-derived EVs isolated under MPTP-treated conditions were associated with increased microglial activation, whereas pharmacological inhibition of EV biogenesis attenuated this response. Mechanistically, EV exposure was associated with inflammatory responses involving NIMA-related kinase 7 (NEK7)-NOD-like receptor family pyrin domain-containing 3-associated inflammatory signaling and IL-1β maturation. Consistent with these findings, NEK7 deficiency attenuated microglial activation and dopaminergic neuron loss in vivo. Together, these findings suggest that renal stress-associated EVs may be involved in linking peripheral stress to central neuroinflammatory responses. This study provides a tentative but verifiable framework for renal stress-EV-inflammasome communication in toxin-induced neuroinflammation.
中文摘要:系统性暴露于MPTP等神经毒素可同时影响中枢神经系统和周围器官,但周围器官应激对神经炎症的贡献仍未充分了解。我们提出一种由外周向中枢的信号传导机制,其中肾脏应激相关细胞外囊泡与微胶质细胞炎症小体激活相关。通过计算与生化方法,组织蛋白酶D被鉴定为MPTP代谢物MPP+的分子靶点。MPP+在肾组织蓄积,并与溶酶体应激和肾小管损伤相关,同时伴有富集肾损伤标志物的循环EV释放增加。药理学抑制对pepstatin A敏感的溶酶体蛋白酶活性可减轻肾损伤和EV释放。MPTP暴露还与血脑屏障破坏相关,可能使循环EV相关信号影响中枢神经系统。在MPTP处理条件下分离的血浆来源EV与微胶质细胞激活增加相关,而药理学抑制EV生成可减弱这一反应。机制上,EV暴露与涉及NIMA相关激酶7(NEK7)-NOD样受体家族含pyrin结构域3(NLRP3)相关炎症信号和IL-1β成熟的炎症反应相关。与这些发现一致,NEK7缺陷在体内减弱微胶质细胞激活和多巴胺能神经元丢失。这些发现提示,肾脏应激相关EV可能参与将外周应激与中枢神经炎症反应联系起来。该工作为毒素诱导神经炎症中的肾脏应激-EV-炎症小体通讯提供了一个初步但可验证的框架。
6神经重症与脑损伤 (2篇)
临床研究 (1篇)
Childhood maltreatment (CM) is a risk factor for adult post-traumatic symptoms and white matter (WM) alterations. It remains unknown how WM microstructure is affected alongside two common military conditions, post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). Data from 299 participants (53% male, 35.69 ± 12.23 years of age) of the Injury and Traumatic Stress (INTRuST) clinical consortium was analyzed. The study included 56 individuals with PTSD (41 with comorbid mTBI), 107 with mTBI, and 136 controls (no PTSD and/or mTBI). Diffusion parameters (mean, axial, and radial diffusivity, MD, AD, RD; fractional anisotropy, FA) in major WM tracts were extracted from diffusion MRI. CM was assessed using the Childhood Trauma Questionnaire (CTQ). Multiple regression models examined associations between CM severity and WM diffusion. Moderation analyses assessed the effect of PTSD and/or mTBI on these associations. Mediation analyses examined how WM diffusion affects the associations between CM and both PTSD and post-concussive symptom severity. Greater CM severity was associated with lower MD and AD, independent of PTSD and/or mTBI. WM diffusion, particularly in the corpus callosum and the superior longitudinal fasciculus, mediated the associations between CM severity and both PTSD (MD bab = 0.022, AD bab = 0.019-0.034) and post-concussive symptoms (MD bab = 0.028-0.040, AD bab = 0.032-0.047). Findings suggest that WM alterations are more strongly associated with CM itself than with either PTSD and/or mTBI. Mediating effects in regions critical for sensory integration highlight the role of WM microstructure as a neurobiological pathway through which CM might predispose to post-traumatic symptoms.
中文摘要:童年期虐待(CM)是成人创伤后症状和白质(WM)改变的风险因素。在创伤后应激障碍(PTSD)与轻度创伤性脑损伤(mTBI)这两种常见军事相关状况并存时,WM微结构如何受影响仍不清楚。分析损伤与创伤应激(INTRuST)临床联盟299名参与者数据(53%男性,年龄35.69±12.23岁)。研究包括56名PTSD个体(41名合并mTBI)、107名mTBI个体和136名对照(无PTSD和/或mTBI)。从扩散MRI提取主要WM纤维束的扩散参数(平均、轴向和径向扩散率,MD、AD、RD;各向异性分数,FA)。CM用童年期创伤问卷(CTQ)评估。多元回归模型检验CM严重程度与WM扩散的关联。调节分析评估PTSD和/或mTBI对这些关联的影响。中介分析检验WM扩散如何影响CM与PTSD及脑震荡后症状严重程度之间的关联。CM严重程度越高与MD和AD越低相关,且独立于PTSD和/或mTBI。WM扩散,尤其胼胝体和上纵束,在CM严重程度与PTSD(MD bab=0.022,AD bab=0.019-0.034)及脑震荡后症状(MD bab=0.028-0.040,AD bab=0.032-0.047)的关联中起中介作用。结果提示,WM改变与CM本身的关联强于其与PTSD和/或mTBI的关联。感觉整合关键区域的中介效应凸显WM微结构作为神经生物学通路的作用,CM可能经此通路易感创伤后症状。
基础研究 (1篇)
The glymphatic system clears cerebral waste, yet strategies to enhance its function remain elusive. Here, we show that 40.68 MHz ultrashort wave (USW) rapidly enhances glymphatic bulk flow in healthy mice within 10 minutes. USW potentiates both glymphatic influx and efflux, concomitant with increased Delta wave neuronal synchronization, as confirmed by local field potentials and electroencephalograms. Chemogenetic silencing confirms that USW-driven glymphatic enhancement depends on neuronal activity, while pharmacological blockade of aquaporin-4 (AQP4) abolishes the effects, revealing dual reliance on neural dynamics and astrocytic water channels. Mechanistically, USW-induced Delta oscillations promote AQP4 polarization, coupling synchronized firing to perivascular AQP4 redistribution. Moreover, USW ameliorates traumatic brain injury-induced cerebral edema and improves cognitive deficits in Alzheimer's mice by restoring glymphatic function. Our findings establish USW as a non-invasive neuromodulatory strategy for enhancing glymphatic clearance, offering therapeutic potential for neurological disorders characterized by glymphatic dysfunction.
中文摘要:类淋巴系统负责清除脑内废物,但增强其功能的策略仍不明确。本研究报告40.68 MHz超短波(USW)可在10分钟内快速增强健康小鼠的类淋巴整体流。USW增强类淋巴流入和流出,同时伴随δ波神经元同步化增强,局部场电位和脑电图证实了这一点。化学遗传学沉默证实USW驱动的类淋巴增强依赖神经元活动,而药理学阻断水通道蛋白4(AQP4)可消除该效应,显示其双重依赖神经动力学和星形胶质细胞水通道。机制上,USW诱导的δ振荡促进AQP4极化,将同步放电与血管周围AQP4重分布耦联。此外,USW通过恢复类淋巴功能改善创伤性脑损伤所致脑水肿,并改善阿尔茨海默病小鼠的认知缺陷。这些发现确立USW作为一种增强类淋巴清除的无创神经调控策略,为以类淋巴功能障碍为特征的神经系统疾病提供治疗潜力。
7多发性硬化与神经免疫 (2篇)
基础研究 (2篇)
Temperature extremes linked to climate change are becoming more frequent and more intense. This has significant implications for human health, including conditions driven by immune dysregulation. There is growing evidence that external thermal stress, particularly heat, may influence both the development and clinical course of several autoimmune conditions. Heat and cold can alter immune cell function through effects on cell signalling, cytokine production, barrier integrity and stress response within tissues. These mechanisms provide a strong biological basis for the observed associations between seasonal or regional temperature patterns and rates of autoimmune disease onset, symptoms, or flare frequency. Temperature extremes present considerable specific health risk to people with autoimmune disease with examples including heat waves worsening fatigue and neurological symptoms in people with multiple sclerosis and cold spells triggering blood vessel constriction and extremity tissue necrosis in systemic sclerosis. As climate instability increases, people with autoimmune disease will face higher clinical risk, due to disease-related factors and increased risks from cardiovascular related morbidity and mortality and concomitant demographic and socio-economic factors. This highlights the need for climate-aware healthcare, patient education, and research that addresses the interface of environmental factors with immune and clinical outcomes.
中文摘要:与气候变化相关的极端温度正变得更频繁、更强烈。这对人类健康有重要影响,包括免疫失调驱动的疾病。越来越多证据表明,外部热应激,尤其是高温,可能影响多种自身免疫病的发生和临床病程。高温和寒冷可通过影响细胞信号传导、细胞因子产生、屏障完整性和组织内应激反应来改变免疫细胞功能。这些机制为季节性或以区域温度模式与自身免疫病发病、症状或复发频率之间的关联提供了强生物学基础。极端温度给自身免疫病患者带来相当大的特定健康风险,例如热浪加重多发性硬化患者的疲劳和神经系统症状,寒潮触发系统性硬化患者的血管收缩和肢端组织坏死。随着气候不稳定性增加,自身免疫病患者将面临更高临床风险,原因包括疾病相关因素,以及心血管相关发病和死亡风险增加,还有伴随的人口学和社会经济因素。这凸显了需要具备气候意识的医疗保健、患者教育,以及针对环境因素与免疫和临床结局交界面的研究。
The meninges are a gateway for pathogenic T cells to enter the central nervous system (CNS). They possess a diverse repertoire of immune cells that orchestrate CNS inflammation and autoimmunity, yet the underlying mechanisms are poorly understood. Here, we report that group 2 innate lymphoid cells (ILC2s) accumulated in the dura as experimental autoimmune encephalomyelitis (EAE) progressed. Single-cell RNA sequencing and flow cytometry analyses revealed distinct features of ILC2s, including expression of MHC class II. ILC2s acted as antigen-presenting cells to activate and expand myelin-reactive T cells in an MHC class II-dependent manner. ILC2-mediated expansion of myelin-reactive T cells increased expression of cytokines IFN-γ and IL-17A. Genetic ablation of ILC2s or of H2-Ab1 in ILC2s alleviated neuroinflammation and CNS demyelination during EAE. These findings revealed a role of ILC2s in neuroinflammation via instructing myelin-reactive T cells, implying targeting ILC2s may be an avenue to restrict CNS inflammation and autoimmunity.
中文摘要:脑膜是致病性T细胞进入中枢神经系统(CNS)的门户。脑膜具有多样的免疫细胞库,协调CNS炎症和自身免疫,但其潜在机制仍不清楚。本研究报告,在实验性自身免疫性脑脊髓炎(EAE)进展过程中,2型固有淋巴细胞(ILC2s)在硬脑膜中积聚。单细胞RNA测序和流式细胞术分析揭示了ILC2s的独特特征,包括表达MHC II类分子。ILC2s作为抗原提呈细胞,以MHC II类分子依赖的方式激活并扩增髓鞘反应性T细胞。ILC2s介导的髓鞘反应性T细胞扩增增加了细胞因子IFN-γ和IL-17A的表达。遗传性清除ILC2s或清除ILC2s中的H2-Ab1可减轻EAE期间的神经炎症和CNS脱髓鞘。这些发现揭示了ILC2s通过指导髓鞘反应性T细胞在神经炎症中的作用,提示靶向ILC2s可能是限制CNS炎症和自身免疫的途径。
8神经遗传/影像与基础转化 (1篇)
基础研究 (1篇)
APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease, yet the cellular mechanisms linking APOE variants to disease risk remain unclear. We previously found that APOE4 expression causes lipid droplet accumulation in oligodendrocytes, reducing myelination, but the underlying mechanisms were unknown. Using a genome-wide CRISPR screen and assay for transposase-accessible chromatin (ATAC) sequencing in human-induced pluripotent stem cell (iPSC)-derived oligodendrocytes, we identified decreased Wnt signaling and overactive glycogen synthase kinase-3 beta (GSK3B) as key regulators of lipid-droplet accumulation. Genetic and pharmacological inhibition of GSK3B reduced lipid droplets in APOE4 oligodendrocytes and increased myelination in three-dimensional iPSC-derived brain organoids. Pharmacological GSK3B inhibition also reduced lipid droplets and improved myelination in APOE4;PS19 tau transgenic mice. Together, these findings establish a mechanistic framework linking Wnt/GSK3B signaling to APOE4-driven disruptions in oligodendrocyte lipid metabolism and myelination, pointing to GSK3B as a potential therapeutic target for APOE4-associated Alzheimer's disease.
中文摘要:APOE4是迟发性阿尔茨海默病最强的遗传风险因素,但将APOE变异与疾病风险联系起来的细胞机制仍不清楚。我们此前发现,APOE4表达会引起少突胶质细胞脂滴积累并降低髓鞘形成,其潜在机制未知。在人类诱导多能干细胞(iPSC)来源的少突胶质细胞中,我们使用全基因组CRISPR筛选和转座酶可及染色质测序(ATAC测序),发现Wnt信号减弱和糖原合成酶激酶3β(GSK3B)过度活跃是脂滴积累的关键调控因素。遗传学和药理学抑制GSK3B可减少APOE4少突胶质细胞中的脂滴,并增加三维iPSC来源脑类器官中的髓鞘形成。药理学抑制GSK3B还可减少APOE4;PS19 tau转基因小鼠中的脂滴并改善髓鞘形成。这些发现建立了将Wnt/GSK3B信号与APOE4驱动的少突胶质细胞脂质代谢和髓鞘形成紊乱联系起来的机制框架,提示GSK3B是APOE4相关阿尔茨海默病的潜在治疗靶点。
9头痛与疼痛 (1篇)
临床研究 (1篇)
Migraine affects individuals of reproductive age, but treatment options during pregnancy are limited due to safety concerns. Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are effective for migraine prevention; however, CGRP is important in placental development. To determine whether early pregnancy exposure to anti-CGRP mAbs or propranolol is associated with spontaneous abortion compared with no exposure. This retrospective cohort study used data from the AM-PREGNANT cohort, derived from the Merative MarketScan Commercial Database, from 2018 to 2021. Participants were followed up through 20 weeks' gestation or until spontaneous abortion or censoring. Among 7 991 200 pregnancies identified in the AM-PREGNANT cohort, 7119 individuals contributing 7579 singleton pregnancies met the predefined eligibility criteria, including age 15 to 45 years, continuous insurance enrollment, last menstrual period (LMP) on or after November 1, 2018, pregnancy end or 20-week censoring by December 31, 2021, and pregestational migraine, defined as a migraine diagnosis or triptan or ergot prescription within 6 months before LMP. Data were analyzed in early 2026. Anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) or propranolol, defined as 1 or more filled prescription or injection procedure claim during follow-up and modeled as time-varying. Spontaneous abortion occurring at 20 weeks' or less gestation. Multivariable Cox proportional hazards models adjusted for comorbidities and concomitant medications estimated the risk of spontaneous abortion. Among 7579 pregnancies in 7119 individuals (mean [SD] age, 31.6 [5.5] years), 1862 spontaneous abortions occurred. There were 100 spontaneous abortions (28.6%) during anti-CGRP mAb-exposed person-time, compared with 37 events among propranolol-exposed person-time without anti-CGRP mAbs (12.8%). Compared with unexposed individuals, anti-CGRP mAbs exposure was associated with an increased risk of spontaneous abortion (adjusted hazard ratio [aHR], 1.42; 95% CI, 1.12-1.80), which remained similar in bias-adjusted analyses (HR, 1.33; 95% simulation interval [SI], 1.23-1.45). Propranolol exposure was not associated with increased risk (aHR, 1.02; 95% CI, 0.71-1.47; bias-adjusted HR, 1.00; 95% SI, 0.96-1.03). In this study, early pregnancy exposure to anti-CGRP mAb was associated with a higher risk of spontaneous abortion, while no association was observed with propranolol. These findings support further evaluation of anti-CGRP mAb safety and emphasize counseling for individuals of childbearing potential.
中文摘要:偏头痛影响育龄人群,但出于安全性顾虑,妊娠期治疗选择有限。抗降钙素基因相关肽(CGRP)单克隆抗体对偏头痛预防有效,但CGRP在胎盘发育中具有重要作用。本研究旨在判断与未暴露相比,早孕期暴露于抗CGRP单克隆抗体或普萘洛尔是否与自然流产相关。这项回顾性队列研究使用AM-PREGNANT队列数据,数据来源于Merative MarketScan Commercial Database,时间范围为2018年至2021年。参与者随访至妊娠20周,或直至自然流产或删失。在AM-PREGNANT队列识别的7 991 200例妊娠中,7119人贡献的7579例单胎妊娠符合预设入选标准,包括年龄15至45岁、保险连续参保、末次月经(LMP)在2018年11月1日或之后、妊娠结束或20周删失发生在2021年12月31日或之前,以及孕前偏头痛,定义为LMP前6个月内已有偏头痛诊断或曲普坦类或麦角类处方。数据于2026年初分析。抗CGRP单克隆抗体(erenumab、fremanezumab、galcanezumab、eptinezumab)或普萘洛尔暴露定义为随访期间有1次或以上处方配药或注射操作理赔记录,并按时间变化变量建模。结局为妊娠20周或以内发生的自然流产。多变量Cox比例风险模型校正合并症和合并用药,估计自然流产风险。7119人共7579例妊娠(平均[SD]年龄31.6[5.5]岁)中发生1862例自然流产。抗CGRP单克隆抗体暴露人时中发生100例自然流产(28.6%),而无抗CGRP单克隆抗体的普萘洛尔暴露人时中发生37例事件(12.8%)。与未暴露者相比,抗CGRP单克隆抗体暴露与自然流产风险升高相关(校正风险比[aHR]1.42;95%CI 1.12-1.80),偏倚校正分析结果相似(HR 1.33;95%模拟区间[SI]1.23-1.45)。普萘洛尔暴露未与风险升高相关(aHR 1.02;95%CI 0.71-1.47;偏倚校正HR 1.00;95%SI 0.96-1.03)。本研究中,早孕期暴露于抗CGRP单克隆抗体与自然流产风险升高相关,而普萘洛尔未观察到这种关联。这些发现支持进一步评估抗CGRP单克隆抗体的安全性,并强调对育龄个体进行咨询。